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1! Introduction 
 
1.1! Neuropilins  
 
Neuropilins (NRPs) were first described in the optic nerve fibers of Xenopus laevis and were named 
after the specific binding area of the antibody A5, called “neuropile” (Takagi et al., 1987). The NRP 
family consists of two proteins, NRP1 and NRP2. The NRPs were identified as neuronal receptors for 
certain semaphorins (sema) and are involved in axon growth and guidance (Kitsukawa et al., 1995; 
Kolodkin et al., 1997; Takagi et al., 1987). In addition to neurons, the NRPs are widely expressed in 
various tissues and cell types like endothelium (reviewed in (Wild et al., 2012)), immune cells (reviewed 
in (Chaudhary et al., 2014; Schellenburg et al., 2017)) and different tumors (Bielenberg et al., 2006; 
Gaur et al., 2009; Prud'homme and Glinka, 2012).  
Neuropilins are single transmembrane glycoproteins with a short cytoplasmic tail of $44 amino acids. 
Both NRPs share the same general structure. Two complement C1r/C1s, Uegf, Bmp1 (CUB) domains are 
N-terminal located followed by two Factor V/VIII (pronounced factor five/eight) domains. A MAM 
domain (c) is localized between the second Factor V/VIII domain and the membrane (Fig. 1). Many 
splice variants are known in humans and mice for NRPs. Among these are two soluble forms in humans 
for NRP1 and one for NRP2 (Rossignol et al., 2000). Depending on the splice forms, NRP1 and NRP2 
are up to 44 % homologous. In detail, they share 55 % of the sequence in the CUB domain, 48 % in the 
Factor V/VIII, 37 % of the MAM (c) domain and 49 % of the transmembrane and intracellular domain 
(Fig. 1). Also, they are similar in size with an atomic mass of approximately 120-140 kDa and share 
biological properties (Prud'homme and Glinka, 2012; Rossignol et al., 2000).  
They are known to function as a co-receptors. NRPs can bind to different groups of ligands, including 
transforming growth factor-beta (TGF-#1), vascular endothelial growth factors (VEGFs), semaphorin 
and other growth factors (GFs), and are therefore involved in the signal cascade for the corresponding 
receptors like VEGFRs, T#RI/T#RII and plexins ((Prud'homme and Glinka, 2012). Intracellular SEA 
domain can interact with the PDZ domain denoted to neuropilin-1 interacting protein (NIP) or GAIP 
interacting protein 1 (GIPC1) (Cai and R. R. Reed, 1999; Muders et al., 2006; Valdembri et al., 2009). 
It is interesting to note, that NRPs interact with five different groups of receptors and/or ligands and 
therefore it is likely that they have different downstream functions. It is commonly accepted that NRPs 
function mostly as an enhancer for the response triggered through their co-receptor. Therefore, the NRPs 
can be involved in many pathways including p38MAPK, ERK1/2, Akt, NF-%B, Smad, and FAK, among 
others (Y. Cao et al., 2010; Coma et al., 2011; Fujii et al., 2016; Fung et al., 2016; Luo et al., 2016; Ou 
et al., 2015; Po et al., 2017; Tu et al., 2016). These proteins have different downstream effects and 
underline the many functions of NRPs. In addition to the axon guidance, which is triggered through the 
plexin receptor, NRPs are known to play a role in many other processes (Prud'homme and Glinka, 2012). 
For example, the interaction of NRPs with VEGFRs is important for the angiogenesis and 
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lymphangiogenesis (Simons et al., 2016), along with cell migration, proliferation and survival (Cariboni 
et al., 2011; Fantin et al., 2009; Kim et al., 2009). 
Because of the broad expression of NRPs and the many ligands and co-receptors, it is likely that many 
functions of NRPs are still unknown. The importance of NRPs was further clarified through knock-out 
models. A knock-out of NRP1 is embryonic lethal and NRP2 knock-out leads to a decrease of the 
lymphatic system and capillaries. Furthermore, the central and peripheral nervous system is impaired 
(Kawasaki et al., 1999; Yuan et al., 2002). Also, an overexpression of NRP1 leads to an abnormal 
development of the heart, blood vessels, capillaries and nerve fibers and is embryonic lethal at 12,5 days 
(Kitsukawa et al., 1995). 
 
Fig. 1: Structure of neuropilins. The neuropilins consist of two CUB domains, followed by two V/VIII factor 
domains. A MAM (c) domain is located directly before the cell membrane. Intracellular is a short cytoplasmic part 
which ends for NRP2a and NRP1 with a SEA domain. NRP2 has two major splice variants, NRP2a and NRP2b. 
Also, a soluble form exists named sNRPb or S9. NRP2a and NRP2b can have five additional amino acids 
(GENFK). Both NRPs have semaphorin and VEGF binding sites, which are different between NRP1 and NRP2. 
55 % of the CUB domains are homologous, 48 % of the V/VIII domain, 37 % of the MAM domain. The 
transmembrane and the cytoplasmic part are to 49 % homologous between NRP1 and NRP2a. But NRP2a and 
NRP2b share only 11 % of the amino acid sequence in their C-terminal region. (adapted from (Schellenburg et 
al., 2017)) 
 
It is important to note, that NRP1 and NRP2 are not only similar, and might both originate through gene 
duplication, but also differ in their binding capacity for ligands (Rossignol et al., 2000). Whereas 
VEGF-A (165) binds to both NRPs, VEGF-A (145) exclusively binds to NRP2. Both NRPs can bind 
semaphorin3B, C and D, but only NRP1 interacts with semaphorin3A. NRP2 has a much stronger 
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affinity to semaphorin3D and F (Gaur et al., 2009; Neufeld and Kessler, 2008; Prud'homme and Glinka, 
2012). 
Both NRP1 and NRP2 are expressed in various kind of tissues and cells including endothelial cells, 
melanocytes, neurons, osteoblasts and pancreatic islets, but not necessarily to the same extent. Whereas 
NRP1 is predominantly expressed in endothelial cells of arteries, NRP2 is found in endothelial cells of 
veins and lymphatic vessels (Bielenberg et al., 2006; Jubb et al., 2012a; 2012b; Wild et al., 2012). 
Because of the expression of NRP2 in many tumors, they came into focus as biomarkers and targets for 
therapies. The expression of NRP1 and NRP2 varies depending on the tumor origin, developmental 
stage, primary tumor and metastasis (Jubb et al., 2012b; 2012a; Prud'homme and Glinka, 2012; Samuel 
et al., 2011). Whereas many researchers studied NRP1 in the last two decades, NRP2 came more into 
focus in the last 10 years (Fig. 2). Because the functions and roles of NRP2 are up to now poorly 
understood or insufficiently analyzed, we focused on studying NRP2. 
 
 
Fig. 2: Number of publications for neuropilins. The graphic shows the publications in pubmed for NRP1 and 
NRP2. A lot more papers exist regarding NRP1 with around 59 new ones every year from 2014, whereas only 
around 24 new papers were published for NRP2. For both NRPs the number of publication every year is 
increasing. (source pubmed.com 12.10.2017) 
 
 
1.1.1! Neuropilin-2 
 
NRP2 can form homodimers in addition to heterodimers with NRP1 and has two main splice variants 
named NRP2a and NRP2b, which can be further divided. Four possible splice variants exist for NRP2a 
and are named according to the number of added amino acids, NRP2a (0), NRP2a (5), NRP2a (17) and 
NRP2a (22). For NRP2a (22), a different splice acceptor is active and localized in intron 15 resulting in 
an addition of five amino acids (GENFK) (Fig. 1). In intron 15 of the NRP2 gene the exon 16b was 
identified. It has a total of 912 bp including a coding sequence of 283 bp, a stop codon and a 3´UTR 
with a polyadenylation signal. This exon can lead to an alternative splicing of NRP2 resulting in NRP2b. 
Two possible splice variants for NRP2b are known, NRP2b (0) and NRP2b (5), which again includes 
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4 
the GENFK sequence. The soluble form of NRP2 named S9 or sNRP2b is generated by intron inclusion 
with an in-frame stop codon. S9 consists of the two CUB domains and the Factor V/VIII domain b1. It 
is interesting to note, that the insertion occurred in the second Factor V/VIII domain b2 because these 
two domains form an integral unit (Appleton et al., 2007; Parker et al., 2015). Also, the S9 is soluble 
and has most of the binding regions of the whole NRP2. Therefore, it can function as an inhibitor by 
covering the binding domains for NRP2. In fact, it is a potent inhibitor for VEGF-C and it can function 
as a specific inhibitor for some pathways (Parker et al., 2015). 
 
NRP2a and NRP2b have the same extracellular sequence, whereas NRP2a has a similar intracellular 
sequence to NRP1 (49 %), including a PDZ binding domain with C-terminal SEA sequence. 
Intracellular NRP2b is very different with only 11 % of the same sequence as NRP2a (Fig. 1) (Rossignol 
et al., 2000). Therefore, it is likely that NRP2a and NRP2b can have different functions. 
Furthermore, NRP2 is one of the eight known proteins (neuronal 
adhesion molecule (NCAM/CD56), CD36, C-C chemokine receptor 
type 7 (CCR7), E-selectin ligand-1 (ESL-1), synaptic cell adhesion 
molecule SynCam-1, sodium channel & subunit, NRP1) which can be 
post-translationally modified by polysialylation (reviewed in 
(Schellenburg et al., 2017). In contrast to NRP2, NRP1 hardly carries a 
sialylation which is caused by the different MAM domain of NRP1. 
NRP2b is more easily sialylated than NRP2a, which again shows the 
difference between the two major splice variants of NRP2 and supports 
the hypothesis that NRP2a and NRP2b can have different functions 
(Bhide et al., 2016; Galuska et al., 2017; Rollenhagen et al., 2013). Two 
enzymes are responsible for the polysialylation. Alpha-2,8-
sialyltransferase 8B (ST8Sia II) and CMP-N-acetylneuraminate-poly-
alpha-2,8-sialyltransferase (ST8Sia IV), whereas only ST8Sia IV is 
facilitating the sialylation of NRP2 (Curreli et al., 2007). The 
polysialylation in case of NRP2 is an O-linked glycosylation and is 
localized between the MAM domain and the Factor V/VIII b2 domain. 
Up to four sides can carry the negatively charged modification, with 
between 8 – 100 &2,8-linked sialic acid residues (Rollenhagen et al., 
2013; Sato and Kitajima, 2013). Polysialic acid is involved in many 
processes including migration, anti-adhesion, development of the 
nervous system, cell-cell and cell-matrix interaction, phagocytosis and T cell activation, and can 
therefore be an important modification for the function of a receptor like NRP2b and to a lesser extent 
NRP2a (Bhide et al., 2016; Drake et al., 2009; Rutishauser, 2008; Stamatos et al., 2014). Another 
difference of NRP2a and NRP2b is their expression. Rossignol et al analyzed tissue with Northern Blots 
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Fig. 3: Posttranskriptional 
sialylations of NRP2. NRP2 
can carry up to 4 polysialic 
acids at 4 O-glycosylation sides 
between the V/VIII factor and 
the MAM domain. 
(Schellenburg et al., 2017)  
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and found out that NRP2a is preferentially present in the brain, liver, lung, small intestine, kidney and 
heart while NRP2b is mainly expressed in the heart and skeletal muscles (Rossignol et al., 2000). It is 
important to note that the human and murine NRP2 are more than 94 % homologous (Schellenburg et 
al., 2017). 
In the last decade, more and more properties were elucidated about NRP2 but not much is known about 
the downstream effects. Also, a distinction between the isoforms NRP2a and NRP2b is currently gaining 
more attention in the research field.  
 
 
1.1.2! Neuropilin-2 in cancer 
 
NRP2 is expressed in various kinds of tumors including bladder (Keck et al., 2015; Sanchez-Carbayo et 
al., 2003), neuroblastoma (Beierle et al., 2004), small and non-small cell lung carcinoma (Lantuéjoul et 
al., 2003), prostate cancer (Muders et al., 2009b) and pancreatic cancer (Cohen et al., 2001; Fukahi et 
al., 2004), but the expression can differ regarding the NRP2 positive cancerous cell number in the tumor 
or the amount of NRP2 in these cells. In addition, not all researchers distinguished between positively 
stained tumor cells or vasculature. Also, not every tumor known for its expression of NRP2 is always 
expressing NRP2 (Jubb et al., 2012a). Therefore, NRP2 was analyzed for its potential as a prognostic 
marker in cancer. In fact, we and others were able to show that a high expression of NRP2 is an 
independent marker for a poor prognosis in bladder cancer (Keck et al., 2015) and breast cancer (Ghosh 
et al., 2008; Yasuoka et al., 2009). Another study in PDACs showed again a correlation between a high 
NRP2 expression and a poor prognosis on mRNA level (Y. Cao et al., 2013). Furthermore, 
Grandclement et al. showed that a forced expression of NRP2 in tumor cells leads to an increased tumor 
growth. On the other hand, a knock-down of NRP2 impaired the tumor formation and tumor growth, 
and correlated with an increase of apoptosis in colorectal cancer (Grandclement et al., 2011; Gray et al., 
2008).  
Because of the many different ligand groups of neuropilins, they can be involved in various processes 
in tumors. Not all researchers distinguished between NRP1 and NRP2 in the beginning, therefore novel 
functions for either of the NRPs needs to be further investigated. So far it is known that they are involved 
in proliferation, migration, invasion, adhesiveness, chemoresistance and metastasis in tumors 
(Bachelder et al., 2001; Chabbert-de Ponnat et al., 2006; Pellet-Many et al., 2008; Prud'homme and 
Glinka, 2012).  
Already, some unique functions and mechanisms for NRP2 in cancer are known. A blockage of 
NRP2/VEGF-C in mammary cancer and melanoma cells impairs the migration, tumor 
lymphangiogenesis and metastasis in vivo (Caunt et al., 2008; Moriarty et al., 2016). Furthermore, NRP2 
is involved in chemotherapy resistance. One possible pathway is through #-catenin (Samuel et al., 2011) 
or through the activation of autophagy. Autophagy is a mechanism for self-digesting of damaged or 
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dysfunctional organelles and components. This process is regulated through the NRP2/VEGF-C axis 
and helps to protect cancer cells from chemotherapy drugs (Stanton et al., 2013). Another downstream 
target of NRP2 is insulin-like growth factor-1 receptor (IGF-1R). VEGFR/NRP2 signaling represses 
IGF-1R and an inhibition of NRP2 and IGF-1R completely suppresses tumor growth. Also, in these 
cases NRP2 is a robust biomarker for the efficiency of the IGF-1R therapy (Goel et al., 2012). 
 
In summary, NRP2 is an interesting player for cancer progression, prognosis and therapy in some 
tumors, but its potential as a biomarker for different cancers and its mechanism needs to be further 
elucidated.  
Previously, our lab showed that targeting GIPC in pancreatic cancer cells leads to a reduction of IGF-
1R followed by a reduction of the proliferation of cancer cells. The PDZ domain is essential for this 
mechanism (Muders et al., 2006; 2009a).  
 
To underline the potential of NRP2 as a prognostic marker and a potential target for therapy, we further 
analyzed the correlation between a high NRP2 expression on the survival in PDACs on protein level.  
 
We hypothesize that a high expression of NRP2 correlates in our set up with a poor prognosis in 
pancreatic cancer. 
 
 
1.2! Pancreatic ductal adenocarcinoma  
 
Pancreatic cancer is the 20th most common cancer in the USA with an estimate of 53.670 new cases in 
2017 and about 43.090 will die because of this cancer. It only accounts for 3 % of all cancers in the 
USA, but is responsible for 7 % of all cancer related deaths. The 5-year survival rate depends on the 
stage of the cancer, but does not exceed 14 %. For higher stages, it goes down to almost 1 %. According 
to the Hirshberg foundation and cancer research UK, the prognosis for the 1-year survival rate for 
pancreatic cancer is only by approximately 20 %. Pancreatic cancers can be divided into two major 
groups depending on their origin. The neuroendocrine tumors are very rare with an incidence of 5 %. 
The most common one is the exocrine pancreatic tumor. In most cases, the cancer starts at the ducts of 
the pancreas and is according to the location called pancreatic ductal adenocarcinoma (PDAC) (data 
from the American Cancer Society, Inc. (ACS)). The institute of pathology of the university clinic 
Dresden established a cohort of 207 patients with a PDAC, which we used to support our hypothesis.  
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Fig. 4: Estimated new cancer cases and cancer related deaths in the USA for 2017. a) It was assumed that 
1.688.780 new cancer cases will be diagnosed in 2017 in the USA. Pancreatic cancer is with 53.670 the 20th most 
abundant cancer. For simplicity, only the 20 most common cancers were shown in the graph. b) It was assumed 
that 600.920 humans in the USA will die because of cancer in 2017. The 6th most common cancer-causing death 
is the pancreatic cancer with 43.090 patients. For simplicity, only 20 cancer forms with the most casualties were 
shown in the graph. (data were collected from the ACS) 
 
The immune system plays a major part in disease development and progression which is similarly true 
for cancer. Interestingly, NRP2 was found on many different immune cells, but the functions of NRP2 
in certain immune cells remains mostly unclear. Hence, this work focused on the role of NRP2 in the 
immune system during different inflammations. 
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1.3! The immune system 
 
The immune system is a defense system that consist of various cells, tissues and organs. It must detect 
and fight many different pathogens like viruses and bacteria, help in wound healing and protect against 
diseases including cancer. Because of the many tasks of the immune system, it is very complex, and 
disturbance can lead to impaired function. This can result in autoimmune diseases like multiple sclerosis 
or to a hypersensitivity, as in asthma. Furthermore, a defect in the immune system is associated with 
cancer. In fact, a chronic inflammation as well as an impaired immune system can promote tumor 
development (Grivennikov et al., 2010; Stewart et al., 1995). One important cell type in tumors are 
macrophages (M!) which belong to the immune system. Macrophages can be divided into two major 
groups, M1- and M2-macrophages. M1-macrophages are also called “classic activated macrophages,” 
and have a pro-inflammatory profile. For the in vitro generation of M1-macrophages, lipopolysaccharide 
(LPS) is commonly used as a stimulus. LPS is a molecule expressed by bacteria which causes a strong 
immune response. In contrast, the M2-macropahges, also named “alternative activated macrophages,” 
have an anti-inflammatory character and are in vitro generated through a treatment with the cytokine 
IL-4 (Sinha et al., 2005). This simplified division between pro- and anti-inflammatory macrophages is 
not the real state in vivo, but macrophages can have a more M1-like character or a M2-like character 
and express corresponding cytokines and genes (Mosser and Edwards, 2008). One special population of 
macrophages are the tumor-associated macrophages (TAMs) which exhibit an M2 profile and therefore 
have an anti-inflammatory profile and are pro-tumorigenic (Biswas and Mantovani, 2010; Flavell et al., 
2010; Pyonteck et al., 2013; H.-W. Wang and Joyce, 2010). Macrophages are involved in many 
progresses in cancers including tumor progression, tumor invasiveness, therapy resistance, tumor 
vascularization and metastasis (Condeelis and Weissleder, 2010; Gocheva et al., 2010; Joyce et al., 
2004; Shree et al., 2011; Sidani et al., 2006; Talmadge and Gabrilovich, 2013). But they can also be 
reprogrammed to develop an anti-tumorigenic profile (Hagemann et al., 2008; Pyonteck et al., 2013).  
 
Another important cell type in the immune system are T cells. They are involved in many immune 
responses including recognition and fighting of exogenous cells. They originate from the thymus and 
during their maturation a selection procedure takes place. The selection is very important to sort out the 
T cells which would recognize endogenous cells which would then result in an autoimmune response. 
The T cells have many subpopulations which are involved in many different processes. One way to 
classify the T cells is by their expression of the receptors CD4 and CD8. The CD8+ cells are called 
according to their expression CD8+ T cells or cytotoxic T cells, and are involved in killing cells like 
tumor cells or damaged cells (Ahlers and Belyakov, 2010; Elemans et al., 2012; Laidlaw et al., 2016; 
Quail and Joyce, 2013). CD4+ T cells are also called T helper cells and are involved in the orchestration 
of an immune response. The T helper cells can be further divided into subpopulations. The four major 
populations are Th1, Th2, Th17 and Treg cells. These populations are involved in complex processes. 
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In summary, Th1 cells promoting M1 macrophages, are pro-inflammatory and kill bacteria; Th2 cells 
promote M2 macrophages and fight parasites. Th17 cells fight extracellular pathogens and activate 
CD8+ cells (Kanduri et al., 2015; McKee et al., 2010; Quail and Joyce, 2013; Trial et al., 2013). Treg 
cells are regulatory cells and suppress or downregulate an immune response, for example after an 
inflammation and therefore prevent chronic inflammation (Fig. 5) (Corthay, 2009). CD8+ and CD4+ T 
cells are activated through antigen-presenting cells like dendritic cells (DCs) and then unfold their 
immunologic profile (Visperas et al., 2014). 
 
 
Fig. 5: Maturation of T cells. CD4+CD8+ T cells can either maturate toward CD8+ T cell, also named cytotoxic 
T cell or CD4+ T cells, named T helper cells. The T helper cells can be further divided. The four most common 
ones are Th1, Th2, Th17 and Treg cells with different functions and cytokine expression. 
 
 
1.4! Neuropilin-2 in the immune system 
 
The NRPs seem to be playing an important part in the immune system. Therefore, more researchers 
focus on studying their expression and function in this complex system. In fact, many studies investigate 
the role of NRP1 in different immune cells but not many studies addressed NPR2 so far. NRP1 is known 
for many interesting features, such as being a unique marker for a certain subpopulation of suppressor 
CD4+ T cells and being involved in the suppression of an immune response (Solomon et al., 2011). 
Furthermore, NRP1 is expressed on a small DCs population and plays a role in the response against a 
viral infection. In addition, NRP1 is involved in the interaction of DCs with CD4+ T cells (Dzionek et 
al., 2002; Ouabed et al., 2008; Reizis et al., 2011).  
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The function of NRP2 in the immune system and during an inflammatory response is mostly unknown, 
but many immune cells express NRP2 including macrophages (Aung et al., 2016; Stepanova et al., 2007; 
Verlinden et al., 2013), basophils (de Paulis et al., 2006), DCs (Curreli et al., 2007; Stamatos et al., 
2014) and T cells (Mendes-da-Cruz et al., 2014). At this point, it is not known if neutrophils, eosinophils, 
B cells and Natural killer cells (NK cells) express NRP2.  
It is interesting to note, that monocytes do not express NRP2 but macrophages do (Ji et al., 2009; 
Verlinden et al., 2013). In conclusion, NRP2 is upregulated during the maturation of the M!. The 
regulation or expression of NRP2 in M1- and M2-macrophages is not sufficiently analyzed. Only Ji et 
al. showed that LPS treatment decreases NRP2 level in their approach (Ji et al., 2009). Otherwise, 
researchers showed NRP2 expression in macrophages in different tissues and also in microglia, a special 
kind of macrophage in the brain, after LPS treatment (Verlinden et al., 2013; Werneburg et al., 2016). 
DCsm which also evolved from monocytes express after their maturation NRP2. Interestingly, it was 
shown that NRP2 on DCs can get polysialylated and the posttranscriptional modification of NRP2 is 
involved in the migration of DCs. In addition, NRP2 is taking part in the activation of T cells through 
DCs in the lymphatic tissue (Rey-Gallardo et al., 2010; Stamatos et al., 2014). Both, CD4+ and CD8+ 
T cells express NRP2 but the expression varies depending on the expression of CD4 and CD8. The 
function of NRP2 is so far unknown in the maturated cells, but it was shown that NRP2 is involved in 
the migration of thymocytes, which are T cell progenitor cells (Mendes-da-Cruz et al., 2014).  
 
 
Fig. 6: NRP2 expressing immune cells. Cells circled with green are known to express NRP2 like macrophages, T 
cells (CD4+ and CD8+ T cells), DCs and basophils. The additional circle in blue marked cells with can be 
polysialylated. (Schellenburg et al., 2017) 
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We hypothesize that NRP2 is an important mediator during an immune response due to its broad 
expression in the immune system.  
With different approaches, in vitro and in vivo, we investigated functions of NRP2 in the immune 
system. For that we used a conditional mouse model. 
 
 
1.5! Mouse models 
 
Animal models are powerful and necessary tools for researchers to understand the complexity of an 
organism, the development of organs and cells as well as the formation and progression of diseases. 
Mice and humans have a very similar genetic sequence (94 %), have similar organs, cell types and 
proteins. These similarities among other reasons make mice models the method of choice for a variety 
of questions for many researchers. Due to the limited options to analyze the effectiveness of drugs 
against for example cancer cells or the interaction of the immune cells, in vivo mice models were 
established. These models give the opportunity to analyze treatment effectiveness against an injected 
cancer with the advantage of an in vivo environment including surrounding tissue, stroma and immune 
cells. Furthermore, mice can be genetically modified so that they spontaneously develop a disease like 
cancer. This can even more reflect the real situation in humans. In addition, special genes in certain cells 
can be modified, and therefore a precise study of the role of the resulting proteome in the target cell 
types is possible. In summary, mice models are an essential tool at this point in order to investigate 
certain progresses and give the advantage of specifically engineered mice to the specific need of the 
researcher. (reviewed in (Vandamme, 2015)). 
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2! Methods 
 
 
All buffers, solutions and other consumables were purchased from Merck if not otherwise indicated.  
 
2.1! NRP2 related survival study in human pancreatic ductal 
adenocarcinoma (PDAC) using a Tissue Micro Array (TMA) 
 
The paraffin blocks with pancreatic ductal adenocarcinoma (PDAC) tissue for this study were designed 
and prepared by Prof. Dr. Daniela Aust and Dr. Christian Pilarsky and published in the study from 
(Pérez-Mancera et al., 2012). The experiment was approved by the ethic commission of the TU Dresden 
(EK59032007). 
 
Blocks were cut in 2 !m slides followed by incubation in a heat cabinet for 60 min at 60°C to adhere 
the tissue to the slides. To study the potential relation of two proteins (NRP2 and VEGF-C) on the 
overall survival a double staining was performed using the standard methods for the BenchMark XT 
with the ultralView-Kit/uAP-Red-Kit of the pathology of university hospital Carl Gustav Carus. All 
solutions were bought from Roche or were the recommended materials from the manufacturer if not 
otherwise indicated. The antibodies were bought from Santa Cruz (NRP2, C-9, 1:100) or Invitrogen 
(VEGF-C; 182255, 1:200). For the NRP2 DAB-substrate was used resulting in a brown color whereas 
for VEGF-C AEC-substrate was used and leads to a red color.  
The intensity (1 to 3) of the staining, the percent of stained tumor cells (0, 1<25%, 2<50%,3<75%, 
4>75%) and the co-expression (0 to 1.0 in 0,1 steps) was graded from two separate researchers (one 
pathologist) and the median was formed. Example for the grading are shown in Fig. 11. 
The Kaplan-Meyer curves and significances with the Log-rank tests were calculated with GraphPad 
Prism. 
 
To analyze the expression of NRP2 in macrophages in and around PDACs, a PgM1 (Dako; M0876; 
1:100) and NRP2 double staining was performed with the same protocols. 
!
2.2! Role of NRP2 in the immune system using different mouse models 
 
2.2.1! Mouse lines 
 
All mice were bred and maintained in accordance with the guidelines of the EU or the US and had 
unlimited access to water and food and a normal day-night-cycle was maintained. The experiments were 
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partially performed in Germany (TVV09/2014) or during a scholarship (great!ipid4all) of the Graduate 
Academy of the TU Dresden at the University of Nebraska (Omaha, USA) (IACUC: 1 610-609). 
Mice were kept in IVC (individually ventilated cages) to have a reduced exposure to pathogens and 
other stimuli as noise and smells.  
Offspring were separated from the parents 4 weeks after birth. 
 
For this work, we used the cre-LoxP system to create two mouse lines with a conditional knock-out of 
NRP2 in certain cells. We started with a NRP2LoxP/LoxP C57BL/6 mice which were given as a gift from 
Alex Kolodkin described in the paper of Walz et al. (Walz et al., 2002) and can be bought from Jackson 
lab (Stock number: 006697). Briefly, two LoxP sequences were inserted in the NRP2 gene. The first 
sequence was inserted 272 bp upstream of the start codon (ATG) and the second 992 bp into the first 
intron. The second LoxP site follows a polyA sequence. These mice are normal in behavior and don´t 
have any pathological conspicuousness. The loxP site can be cleaved from the cre-recombinase. The 
cleavage leads to a knock-out of the NRP2 gene and no detectable NRP2 RNA is transcribed in the 
target cells. To get a knock-out in certain cell types, only these specific cells should express the 
cre-recombinase. That is achieved by using the specificity of certain promotors. We used LysM:cre and 
a Vav:cre mouse lines where the cre-recombinase is on one hand under the LysM-promotor and on the 
other hand under the Vav-promotor. Both LysM:cre and Vav:cre mice were a gift from Prof. Wielockx. 
 
2.2.2! LysM:cre-NRP2LoxP/LoxP 
 
The cre-recombinase in LysM:cre mice is expressed in myeloid cells due to the insertion of the cre 
cDNA into the M lysozyme locus as published by Clausen et al (Clausen et al., 1999). A breeding with 
the LysM:cre C57BL/6 mice and the NRP2LoxP/LoxP mice leads to a LysM:cre-NRP2LoxP/+ mouse in the 
1. Filial (F1) generation and to a LysM:cre-NRP2LoxP/LoxP in the F2 generation and were used for the 
final breeding (Fig. 7). The offspring of the final breeding are either LysM:cre-NRP2LoxP/LoxP mice or 
NRP2LoxP/LoxP mice. The LysM:cre-NRP2LoxP/LoxP mice express the cre-recombinase in myeloid cells 
which leads to a cre mediated cut out of the first part of the NRP2 gene including the promotor sequence 
in 83-98 % in mature macrophages, nearly 100 % in granulocytes and 16 % in CD11c+ splenic DCs. T 
cells and B cells are not affected. The NRP2LoxP/LoxP mice were used as a control and were further referred 
to as wt. 
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Fig. 7: Breeding schema to obtain a conditional knock-out mouse. To get a conditional knock-out mouse the cre-
mouse of interest were mated with a NRP2LoxP/LoxP mouse. The offspring in the F1 generation are either NRP2LoxP/+ 
or cre-NRP2Lox/+. The cre-NRP2LoxP/+ were mated with a NRP2LoxP/LoxP to get in the F2 generation among others 
the cre-NRP2LoxP/LoxP which were used with a NRP2LoxP/LoxP for the final breeding.  
 
 
2.2.3! Vav:cre-NRP2LoxP/LoxP 
 
In the Vav:cre C57BL/Bl6 mice (Stadtfeld and Graf, 2005) cre recombinase is under the Vav-promotor 
and these mice were bred again with the NRP2LoxP/LoxP C57BL/6 mice to generate Vav:cre-NRP2LoxP/LoxP 
mice as it was done with the LysM:cre-NRP2LoxP/LoxP and shown in Fig. 7. The Vav-promotor is active 
in fetal hematopoietic progenitors and in all hematopoietic lineages. Therefore, the cut out occurs very 
early during the embryonic stage E10,5 and all cells of the hematopoietic system are targeted. Again, 
the NRP2LoxP/LoxP mice were used as a control and were further referred to as wt.  
 
2.2.4! Genotyping 
 
The genotyping for the mice were performed with the KAPA2G Fast HS Kit from Kapa Biosystems as 
described in the manual and analyzed by a 1,5 % agarose gel. The following primers and programs were 
used in the different PCR: 
 
The PCR were carried out on a Dyad Disciple (BioRad) with the following programs.  
  
!"#$%&'#(%&'#
)*+
)*+,!"#$%&'#(-
!"#$%&'#(-
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!"#$%&'#(-
/0
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Table 1: PCR programs for the different genotyping PCRs. 
 
NRP2   cre   LysM   
Step Temp {°C} Time {min} Temp {°C} Time {min} Temp {°C} Time {min} 
1 95 2 95 3 94   
2 94 00:20 94 01:00 94   
3 65 00:15 67 01:00 55   
4 68 00:15 72 01:00 72   
  
decrease by 0.5°C every cycle 
cycle to step 
2 
30x 
cycle to step 
2 
35x 
5 Cycle to step 2 10 x 72 10:00 72 3 
6 94 00:15 4 forever 12 forever 
7 60 00:15 
    
8 72 00:15 
    
9 Cycle to step 6 28 x 
    
10 72 01:00 
    
11 10 forever 
    
 
 
Table 2: Primers for the genotyping 
Primer 5´- 3´Sequence 
mom0065 AGC TTT TGC CTC AGG ACC CA 
mom0066 CAG GTG ACT GGG GAT AGG GTA  
mom0128 CCT GAC TAC TCC CAG TCA TAG  
cre1 GCC TGC ATT ACC GGT CGA TGC AAC GA 
cre2 GTG GCA GAT CGC GCG GCA ACA CCA TT 
LysM common CTT GGG CTG CCA GAA TTT CTC 
LysM mutant CCC AGA AAT GCC AGA TTA CG 
 
 
2.3! Cell culture 
 
All solutions and consumables were bought from ThermoFisher if not otherwise indicated and were 
delivered sterile or were sterilized before use. All liquids were pre-warmed to 37 °C and all work was 
performed at RT if not otherwise indicated. The bench and other materials were cleaned with 70 % 
ethanol before use. Cells were cultured in incubators at 37 °C and 5 % CO2.  
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2.3.1! Cell lines 
 
LLC (Lewis lung carcinoma) cells are a cell line established from an implanted primary Lewis lung 
carcinoma of a C57BL mouse and were given as a gift from Prof. Wielockx. The cells were stored at -
80 °C in 5 % DMSO, 50 % FCS and 45 % LLC culture medium. Cells were defrosted at RT and 
transferred in a 15 ml falcon with 5 ml culture medium. To separate cells from the toxic DMSO, the 
suspension was centrifuged at 3 min at 300 x g. Next, supernatant was discarded, cells resuspended in 
10 ml culture medium, transferred in a 25 cm2 cell culture flask and incubated in the incubator. They 
grow loosely adherent and before they reach confluency they form multilayers. To avoid multilayer, 
they need to be split when they reach a 70 % confluency. To split the cells medium was removed and 
cells were washed with 5 ml endotoxin-free PBS. Next, PBS was removed and 2 ml of trypsin/EDTA 
was added to the cells. After 2,5 min incubation in the incubator with a followed rocking of the flask to 
detached all cells the trypsinization was stopped with 5 ml of culture medium. The cell suspension was 
transferred in a 15 ml falcon for centrifugation (3 min, 300 x g). The supernatant was discarded, and 
cells resuspended in 5 ml culture medium. 500 !l of cell suspension was transferred in a new 25 cm2 
culture flask.  
 
2.3.2! Primary culture 
 
2.3.3! Isolation and differentiation of bone marrow derived macrophages (BMDM) 
 
For the isolation of BMDM, 6-8 week old LysM:cre-NRP2LoxP/LoxP mice and NRP2LoxP/LoxP mice were 
used. Mice were sacrificed by cervical translocation and the femur and tibia from both legs were isolated. 
Skin and muscles were removed, and the bone kept on ice in 3 % FCS 1 % P/S PBS. Next, the end of 
the bones was cut, and the bone marrow flushed with 3 % FCS 1 % P/S PBS by inserting a 25 g needle 
gauge into the bone. Cells were suspended by pipetting and then centrifuge at 1500 rpm 5 min at 4°C. 
Next, cells were resuspended in 1 ml erythrocyte lysis buffer and incubated for 2 min at RT to clear the 
cells from erythrocytes. The cell suspension was centrifuge again at 1500 rpm 5 min at 4°C. If the cell 
pellets were not white, the lysis was repeated. Cells were washed with 5 ml of 3 % FCS 1 % P/S PBS 
and centrifuged at 1500 rpm 5 min at 4°C. Next, the pellet was resuspended in culture medium, either 
with GM-CSF or M-CSF to differentiate the macrophages towards a M1-like or M2-like character (Fig. 
8). 100.000 cells were plated in each well of a 24-wells plate. Medium was changed every 2-3 days with 
addition of fresh GM-CSF or M-CSF. After 7 days of culture, the medium was removed, and the 
macrophages washed twice with PBS and 0,1 % BSA. RPMI was added to the cells for starvation 
overnight. The next day macrophages were polarized with either 100 ng/ml LPS to induce M1-
macrophage or 20 ng/ml IL-4 to induce M2-macrophages. After 4 hours, the M1-macrophages were 
harvested for gene expression analysis. The M2-macrophages were lysed after 24 hours for gene studies.  
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Fig. 8: Schema of differentiation towards macrophages. Monocytes were treated either with GM-CSF or M-CSF 
to differentiate towards either M1-like macrophages or M2-like macrophages. A subsequent stimulation with LPS 
or IL-4 leads then to M1- or M2-macrophage with specific marker genes. 
 
 
2.3.4! Isolation of primary T cells  
 
Materials and protocols for the isolation of T cells were used from Miltenyi if not otherwise indicated. 
Vav:cre;NRP2LoxP/LoxP C57BL/Bl6 mice and NRP2LoxP/LoxP C57BL/Bl6 mice were sacrificed by cervical 
translocation and the spleen and/or inguinal and brachial lymph nodes were isolated. The tissues were 
put in little dishes filled with ice cold DMEM and put on ice to keep cool during the isolation. Spleen 
and lymph nodes were placed between the rough end of two sterile slides and manually disrupted. 
Furthermore, the suspension was homogenized by pipetting up and down and applied on a filter mesh 
to separate clumps and tissue parts from the cells. The flow through was centrifuge for 10 min at 400 g. 
The supernatant was dismissed and the pellet resuspended in cold 0,5 % BSA/PBS. Cells were counted 
and the required number of cells were centrifuge again for 10 min at 400 g. Supernatant was dismissed 
and cells were used for further experiments.  
  
monocyte
GM-CSF M-CSF
M1-like 
macrophage
M2-like 
macrophage
IL-4LPS
iNOS
Tnf-!
IL-1"
Arg1
Fizz1
Ym1
Ym2
M1-macrophage M2-macrophage
IL-4 LPS
M2-macrophage M1-macrophage
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2.3.5! Isolation of T lymphocytes with positive and negative selection 
 
A positive or negative selection can be used with magnetic beads to isolate cells. For the positive 
isolation, cells of interest are labeled with magnetic beads on their cell membrane and stick to a magnetic 
column. Contrary, in the negative isolation all cells except of the cells of interest are labeled with 
magnetic beads and stick to the column while the cells of interest are passing through. 
 
2.3.6! Isolation of lymphatic and/or splenic CD8+ cells  
 
Cells were isolated as described above at topic 2.3.4 and resuspended in 90 !l cold BSA/PBS buffer. 
For every additional 107 cells 30 !l of BSA/PBS buffer was added. Per 107 cells 10 !l CD8& positive 
isolation beads were added to the suspension and incubated in the refrigerator for 15 min. During the 
incubation, the LS columns were prepared by placing it in the magnetic field and rinsing it with 3 ml of 
BSA/PBS buffer. After centrifugation at 400 x g for 10 min the pellet was resuspended in 500 !l 
BSA/PBS buffer and applied to the columns. When the column reservoir emptied, 5 ml of BSA/PBS 
buffer was added for washing. The flow through was discarded and the cells of interest are bound in the 
column. To detach the cells, the column is taken out of the magnetic field and 5 ml of BSA/PBS is added 
on the column. The plunger was inserted and the liquid pressed through the column. The flow through 
with the cells of interest is collected followed by a centrifugation at 400 x g for 10 min. The cell pellet 
was lysed with 350 !l of RT1 buffer with 1 % #-mercaptoethanol. The samples were stored at -20°C 
until used for RNA isolation. 
 
2.3.7! Isolation of lymphatic and splenic native CD4+ cells  
 
All solutions were sterilized and precooled to 4°C. The work was performed under sterile conditions 
under a hood. 
Cells were isolated as descripted above at topic 2.3.4 and resuspended in 40 !l cold BSA/PBS buffer 
per 107 cells and treated as described in the manual from the naïve CD4+ isolation kit from Miltenyi. 
Briefly, for every 107 cells 10 !l of Biotin-Antibody Cocktail was added to the cells and mixed well by 
pipetting. Next, the suspension was incubated for 5 min in the refrigerator. After that 20 !l of BSA/PBS 
buffer per 107 were added to the cells and as well as 20 !l of Anti-Biotin MicroBeads and 10 !l of CD44 
MicroBeads per 107 cells and mixed well. Cells were incubated for 10 min in the refrigerator while the 
LS columns were prepared by placing the column in the magnetic field and adding 3 ml of BSA/PBS 
buffer. After the incubation cells were centrifuged at 400 x g for 10 min and the supernatant was 
discarded and the pellet resuspended in 500 !l of BSA/PBS. The cell suspension was added to the 
column and the flow through was collected. When the column reservoir was empty 5 ml of BSA/PBS 
was added to wash the unlabeled cells of interest off the column and the flow through was collected. 
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The cell suspension was centrifuged at 400 x g 10 min and the supernatant discarded. The cell pellet 
was resuspended in either RT1 buffer with 1 % #-mercaptoethanol for RNA isolation or in T cell culture 
medium. 
 
2.3.8! Differentiation and culture of naïve CD4+ cells 
 
The naïve CD4 positive cells were resuspended in T cell culture medium, counted and equally split 
between the different situations in 24-well plats. For the differentiations, different cytokines and 
antibodies were added as described in the Table 3. T cell activation beads were prepared as described in 
the manual of the T Cell Activation/Expansion Kit from Miltenyi. The activation beads dependent on 
the cell number were added to the medium in a ratio of 1,5 beads to 1 cells for 2 days. After 2 days of 
culture and activation, the cell clumps need to be dissolved, the medium renewed, and the beads 
removed. To break up the clumps, the medium with cells was pipetted up and down 6 times and the cell 
suspension was put in a 1,5 ml Eppendorf reaction tube. The activation beads are magnetic. Therefore, 
the tube was held against a DynaMag (Invitrogen). After all the beads are together on one spot the cell 
suspension was taken out and transformed into a new tube for centrifugation (400 x g 10 min). The 
supernatant was discarded and the pellet was dissolved in fresh culture medium and the cells put in a 
new 24-well plate. Medium was again changed after another 2 days. After 6 days, the cells were taken 
out, centrifuged and dissolved in RT1 buffer with 1 % #-mercaptoethanol for qPCR analysis. 
 
Table 3: Stimulation for differentiation of CD4 T cells 
 
Th1 Th2 Th17 
IL-1# - - 10 ng/ml 
IL-2 10 ng/ml 10 ng/ml - 
IL-4 - 10 ng/ml - 
IL-6 - - 10 ng/ml 
IL-12 10 g/ml - - 
IL-23 - - 10 ng/ml 
TGF-# human - - 2 ng/ml 
Anti-Il-2 - - 10 !g/ml 
Anti-IL-4 10 !g/ml - 10 !g/ml 
Anti-IFN" - 10 !g/ml 10 !g/ml 
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2.4! Lewis lungs carcinoma model  
 
To analyze the effect of the conditional knock-out in the mouse lines on the tumor pathology a LLC 
mouse model was used.  
One day prior the tumor injection the back of the mice was shaved, and depilatory cream was applied 
for 3 min. The cream and the hair were washed away with a wet paper towel so that the clean hairless 
skin remained. 
The LLCs were cultured as descripted under point 2.3.1. When enough cells were in culture the cells 
were washed, trypsinized and centrifuged. The supernatant was discarded, and the cell resuspended in 
5 ml 4°C endotoxin-free PBS. The cells were centrifuged for another 3 min at 1000 x g. Again, the 
supernatant was discarded, and the procedure was repeated. After the LLCs were resuspended in 4°C 
endotoxin-free PBS the LLCs were counted with a Neubauer chamber. The needed number of cells were 
taken and centrifuged for 3 min at 1000 x g. The LLCs were resuspended in 4°C endotoxin-free PBS to 
get a suspension of the number of cells per tumor in 100 !l of PBS. 100 !l of cell suspension was 
injected on the right and left site of the back of the mice. Every day the length and the weights of the 
tumor was measured, and the volume was calculated with the following formula: (length x weights2)/2 
= tumor volume, whereas length is the longer site of the tumor. The measurement was always performed 
from the same person and blinded. The experiment was stopped when the tumor turned bloody or 
reached a volume above 2000 mm2. Then the mice were sacrificed, and the tumors isolated for further 
analysis. For the stainings the tumors were fixed in 4 ml formalin overnight, followed by a drainage and 
then embedded with paraffin.  
For an analysis with flow cytometry the tumor was transferred in a little dish and 500 !l DMEM with 
2,6 U/ml dispase II, 0,3 U/ml collagenase D and 5 !l/ml DNAse was added. Next, the tumor dissociated 
between two frosted slide edges and pipetting and then incubated for 45 min at 37°C. Pipette up and 
down to dissolve all cell clumps and add 150 !l DMEM with 10 % FCS to stop the reaction. The cell 
suspension was filtered through a 30 !m mesh and further treated as described under point 2.8.  
 
Statistical values were calculated with the Mann! Whitney T! Test using GraphPad Prism. 
 
 
2.5! Immunohistochemistry 
 
2.5.1! Paraffin embedded tissue 
 
For the immunohistochemistry materials and consumables were used from Dako. For the machines, 
solutions and other materials were ordered as the manufacturer recommended. All antibodies were 
diluted as recommended from the manufacturer if not otherwise indicated. 
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2.5.1.1! Fixation 
 
After the tissue was fixed overnight in formalin it was transferred in the Excelsior/STP 420 for 
embedding in paraffin using the standard method of the pathology. The steps are specified in the Table 
4. 
 
Table 4: Program for paraffin embedding with the Excelsior/STP 420 
reagent overnight (hh:mm) 
4 % Formalin 00:30 
4 % Formalin 00:30 
70% alcohol 01:00 
80% Alcohol 01:00 
95% Alcohol 01:00 
99% Alcohol 01:00 
99% Alcohol 01:00 
99% Alcohol 01:00 
Xylol 00:45 
Xylol 00:45 
Xylol 00:45 
Paraffin 01:20 
Paraffin 01:20 
Paraffin 01:20 
Duration 13:29 
 
The tissue in hot paraffin was transferred in a form and the embedding cassette was placed as a cover 
on top. The form was placed on a cooling plate for hardening. After the paraffin was solid the form was 
taken off and the paraffin block with the tissue stored at RT until further processed. 
!
2.5.1.2! Cutting 
!
The paraffin tissues were cut in 2 !m slices using the Leica RM 2135, transferred into a hot water bath 
(50°C) and fixed on a glass slide. The slides were incubated in a heat cabinet for 60 min at 30°C to dry. 
Slides were stored at RT until further processed. 
!
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2.5.1.3! Hydration 
!
Previous to the staining the tissue was pretreated and rehydrated. First, the slides were incubated for 
30 min at 60°C and then rehydrated with the following Xylol/ethanol sequence: 2 x Xylol (15 min, 
10 min), 2 x 100 % ethanol (each 5 min), 2 x 96 % ethanol (each 5 min), 2 x 70 % ethanol (each 5 min) 
and aqua dest. (5 min). 
!
2.5.1.4! H&E 
!
After the rehydration the slides with the tissue were incubated in hematoxylin according to Mayer for 
10 min followed by an incubation in warm and running water for 5 – 10 min depending on the stain. 
Next, the slides were incubated with Eosin for 5 secs followed by a washing step in water. The tissue 
was fixed with Aquatex mounting medium (Merck) and covered with a cover slip. 
!
2.5.2! Evaluation of necrotic areas 
!
Slides were scanned with a iScan Coreo Au Scanner (Ventana) and analyzed with ImageViewer. 
Necrotic areas were identified from a pathologist and encircled. Total tumor areas were compared to the 
necrotic area in percent. The analysis was performed blinded and statistical values were calculated with 
the Mann! Whitney T! Test using GraphPad Prism. 
!
2.5.3! PAS-Staining 
!
After the rehydration the PAS-staining (Periodic-Acid-Schiff) was performed on the Sakura Tissue Tek 
Prisma with the following program: 
!
!
!
! !
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Table 5: Program for the PAS-staining on the Sakura Tissue Tek Prisma 
Step Nr. Bath Reagent Time in min 
1.!  27 Xylol 2:30 
2.!  26 Xylol 2:30 
3.!  25 Absolute Alcohol 1:00 
4.!  24 96 % Alcohol 1:00 
5.!  23 70 % Alcohol 1:00 
6.!  W5-7 Water 0:30 
7.!  14 Periodic acid 5:00 
8.!  W5-7 Water 0:30 
9.!  29 Aqua dest. 0:30 
10.!  17 Schiffs-Reagent 20:00 
11.!  W5-7 Water 3:00 
12.!  19 Hämalaun-Mixture 5:00 
13.!  W5-7 Water 5:00 
14.!  9 70% Alcohol 1:00 
15.!  10 96% Alcohol 1:00 
16.!  21 Absolute Alcohol 1:00 
17.!  22 Xylol 4:30 
  Sum: 55:00 
!
!
2.5.4! CD31 Staining 
!
After the rehydration, the slides were boiled in Target Retrieval Solution (ph 6) in the microwave 
followed by an incubation in an oven for 30 min at 95°C. Next, the tissue was circled with a fat pen and 
one drop of Dual Endogenous Enzyme Block (S2003) per tissue was added and incubated for 10 min. 
Slides were washed 4 x for 5 min with Wash buffer (S3006). For the perforation of the cell membrane 
the tissue was treated with Triton-X solution (NH4Cl 30 g/l, Triton-X 0,25 %) for 10 min. Next, 
unspecific binding sides were blocked using a 5 % BSA/PBS solution (Vecta Kit, Vectoslabs) for 1 h. 
The CD31 antibody (rabbit anti-CD31, Abcam, ab28364) was diluted in 1 % BSA/PBS. The blocking 
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solution was removed and the CD31 antibody solution added on the slides and incubated for 40 min. 
Next, the tissue was washed 4 x for 5 min with Washing Buffer and further treated as described in the 
manual of the Vectastain ABC Kit anti-rabbit. Before the fixation with Aquatex mounting media (Merck 
Millipore, 108562) the tissue was treated for a couple of sec. with Marris Heamatoxylin solution (Sigma-
Aldrich, HH32-1L). 
 
Slides were scanned with a iScan Coreo Au Scanner (Ventana) and analyzed with ImageViewer. 
Statistical values were calculated with the Mann! Whitney T! Test using GraphPad Prism. 
!
2.5.5! Fluorescent staining on frozen tissue against CD31 and CD206 
!
LLC tumor tissue was isolated from mice directly after death of the mice, embedded in OCT Tissue-
Tek (Sakura) and stored at -80°C. The samples were cut with a cryotome (Thermo Fisher) in 4 !m slides, 
dried and stored at -20°C.  
Before starting the staining, the box with the slides was taken out of the freezer and left at RT for 15 min. 
Next, the slides were taken and dried at RT for at least 30 min. Dried slides were fixed with ice cold 
acetone for 10 min at -20°C followed by an incubation for 30 min at RT. From this point forward, slides 
were kept in a humid chamber in the dark. The tissue was encircled with a Pap-Pen (Dako) and washed 
3 x respectively for 5 min with TNT buffer (20 mM Tris, pH 7.8, 0,9 % NaCl, 0,05 % Tween). Next, 
unspecific binding sides were blocked with 5 % goat serum in TNT buffer for 30 min. The primary 
antibodies (rat anti-mouse CD206, Santa Cruz, 1:200 or rat anti-mouse CD31, Ben Wielockx, 1:500) 
were diluted in TNT buffer and incubated at 4°C overnight. The control slide was incubated without 
primary antibody. The next day, slides were washed 3 x respectively for 5 min with TNT buffer. The 
secondary antibody (goat anti-rat IgG Alexa Fluor 555, Cell Signaling 4417, 1:500) was diluted in TNT 
buffer and incubated for 30 min at RT. Next, slides were washed again with TNT buffer 3 x respectively 
for 5 min. The nuclei were stained with DAPI (0,2 !g/ml in PBS) for 5 min at RT followed by 3 washing 
steps with PBS for respectively 5 min. Slides were mounted with fluorescent mounting medium (Dako) 
and stored at 4°C in the dark. 
 
With the Laser Scanning Microscope (LSM 510, Zeiss) and/or the ApoTome (Axiovert 200M, Zeiss) 
the slides were screened and pictures were taken. The analysis was performed using Zen (Zen 2009, 
Zeiss) and ImageJ/Fiji. 
!
2.5.6! Evaluation of fluorescence CD31 and CD206 staining with ImageJ/Fiji 
!
Pictures were transformed to .tif files using Zen and loaded in Fiji. The ROI manager was opened, the 
area of interest encircled by hand and the mask added to the ROI manager. The different channels of the 
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pictures were split and first the DAPI files further used (Fig. 9a&b). With the threshold the tumor area 
was marked and measured (Fig. 9c). Next, the same was done with the red channel (CD31 stain). The 
area in pixel for the DAPI staining and the CD31 stain was calculated. The DAPI area was set to 100 %. 
Statistical values were calculated with the Mann! Whitney T! Test using GraphPad Prism. 
Analogous the CD206/DAPI staining was evaluated. 
!
!
Fig. 9: Analysis of CD31 stain with ImageJ. a) is the DAPI channel and b) is the red channel for the CD31 stain. 
c) shows the measured area in the circle in the DAPI channel. The threshold was set to 13 in this experiment. 
!
!
2.5.7! Evaluation of the amount of M2-macrophages in LLC tumors 
!
From every tumor 4 random sections were chosen and all DAPI positive cells and CD206 positive cells 
were counted. With these numbers the percentage of CD206 positive cells in the tumor were calculated. 
The evaluation was performed blinded. Statistical values were calculated with the Mann! Whitney 
T! Test using GraphPad Prism. 
!
!
2.6! Mild allergic model of the lung  
!
To cause an allergic response in the lung of Vav:cre;NRP2LoxP/LoxP C57BL/Bl6 mice and NRP2LoxP/LoxP 
C57BL/Bl6 mice, mice they were treated with ovalbumin by nasal application similar as published from 
Toussaint 2013 (Toussaint et al., 2013). For the procedure mice were anesthetized with a Ketamine 
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(10 mg/ml)/Xylazine (1 mg/ml)/NaCl solution. Per 1 g bodyweight 10 !l of anesthesia solution was 
applied IP. When the mice were anesthetized 100 !l of 1 !g/!l Ovalbumin was applied on the nose of 
the mice and inhaled from the mice. After the application mice were put back into the cage and the 
recovery was observed. This procedure was repeated at day 12, 13 and 14 with 25 !g Ovalbumin in 
100 !l PBS. At day 15 mice were again anesthetized but this time 1,5 x of anesthesia solution was 
injected. Mice were checked for muscle reflexes at the hind leg. When a muscle contraction was 
triggered, more anesthesia solution was applied, and the reflexes were checked every few minutes. When 
the reflexes stopped at the hind leg, mice fixed at the legs and the head was pulled back to give easy 
access to the trachea. A butterfly was inserted in the trachea and carefully pushed further down towards 
the lung without damaging the tissue. The metal needle was carefully taken out, so that the pipe stayed 
in the trachea. With a syringe, 250- 300 !l of 5 % FCS/PBS was injected through the butterfly into the 
lung. Without taking the syringe out, the liquid was sucked back out and transferred into a new reaction 
tube and put on ice. The washing procedure and collecting the cells was repeated until 2 ml of FCS/PBS 
was injected and taken out again. The cells were centrifuged for 7 min at 2,2 rpm and afterwards 
resuspended in cold FCS/PBS. 10 !l of the cell suspension was taken and stained with anti-CD45 
(eBioscience) for counting at the Macs Quant The other cells were prepared for flow cytometry as 
described in section 2.8.   
Next, mice were sacrificed by cervical translocation and the lungs isolated and transferred in a tube with 
formalin and treated as described at section 2.5. The lungs were cut progressively, and a PAS-staining 
was performed.  
 
 
2.7! Quantitative Real-Time PCR (qPCR) 
 
2.7.1! RNA isolation 
 
Cells were harvested, and the RNA isolation was performed according to the RNeasy Mini Spin Kit 
(Qiagen). The samples were kept on ice and for the centrifugation a pre-cooled centrifuge (5427R, 
Eppendorf) was used. DNA digestion was performed “on-column” and RNA was eluted with 20 !l of 
RNase-free water. RNA concentration was measured with a Nano-Drop (peqlab). 1 ug of RNA in 11 !l 
was taken for the cDNA synthesis. If the concentration was not sufficient, a lower amount was taken 
depending on the lowest sample but for all the same. Water was added to reach in every sample the same 
volume of 11 !l.  
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2.7.2! cDNA synthesis 
 
For the cDNA synthesis, a master mix was prepared containing 4 !l 5 x reaction buffer, 1 !l RiboLock 
RNase Inhibitor (20U/!l), 1 !l random hexamer primer, 2 !l 10 mM dNTP mix, and 1 !l RevertAid 
HMinus M-MuLV Reverse Transcriptase (200 U/!l) for each sample and controls. 9 !l of this master 
mix was added to each RNA sample followed by an incubation for 5 min at 25°C and 60 min at 42°C 
in a DyadDisciple thermal cycler (BioRad). Samples were diluted at least with 20 !l of RNA-free water 
and stored at -20°C. 
 
2.7.3! qPCR 
 
For quantitative real-time PCR, 5 !l of the Maxima SYBR Green qPCR Master Mix (Thermo Scientific) 
was mixed with 1 !l of cDNA and 2,8 !l of ddH2O (Thermo Scientific) for each reaction. Primer mix 
was prepared with 95 !l ddH2O (Thermo Scientific), 2,5 !l forward primer (100 pmol/!l, Eurofins) and 
2,5 !l reverse primer (100 pmol/!l, Eurofins). PCR was set up in doublets with water controls for each 
target gene. Primer sequences are listed below: 
 
Table 6: qPCR primers 
Primer Name Forward Sequence 5’-3’ Reverse Sequence 5’-3’ 
18S AGCTTCCGGGAAACCAAAGT TGTCAATCCTGTCCGTGTCC 
Arg1 GAACACGGCAGTGGCTTTAAC TGCTTAGCTCTGTCTGCTTTGC 
Fizz1 CTGCTACTGGGTGTGCTTGTG GCAGTGGTCCAGTCAACGAG 
IFNy TGAGCTTCCCAGATCACAGA TCCAGAAGGCCCTCAGACTA 
IL-10 TAAGGCTGGCCACACTTGAGA AGCTGCTGCAGGAATGATCA 
IL-13 TGTGTCTCTCCCTCTGACCC CACACTCCATACCATGCTGC   
IL-17 TGAGCTTCCCAGATCACAGA TCCAGAAGGCCCTCAGACTA 
IL-1b ATCCCAAGCAATACCCAAAG GTGCTGATGTACCAGTTGGG 
IL-2 TGGAAAGGTTGAGGGGTAAG ACACCTGTAAGCCCAGCTCT 
IL-4 AGTGAGCTCGTCTGTAGGGCTT GTGGACTTGGACTCATTCATGG 
IL-5 GACGATGAGGCTTCCTGTCC CCACACTTCTCTTTTTGGCGG 
IL-6 CACGGCCTTCCCTACTTCAC TGCAAGTGCATCATCGTTGT 
iNOS ACCTTGTTCAGCTACGCCTT CATTCCCAAATGTGCTTGTC 
NRP1 GCAAGCGCAAGGCTAAGTCG AGCTGTAGGTGCTTCCACTTC 
NRP2 total ACTGGACAGACTCAAAGCCC TCAAAGCTGCAGTTTTCCCC 
NRP2a GACACAGACAGGAGCGCATC GCCATCCTCTTCTGCCTCTT 
NRPb CTGGAGAACTGCATGGAACC GGCCGCCATAACGTAATACC-3 
TNF-& AGCCCCCAGTCTGTATCCTTCT AAGCCCATTTGAGTCCTTGATG 
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VEGFa TACCTCCACCATGCCAAGTG ACAGGACGGCTTGAAGATGTA 
Ym1 TTCTGAATGAAGGAGCCACTGA ACCACGGCACCTCCTCCTAAATTG 
 
 
qPCR was pipetted into a clear 96 well plate (Thermo Scientific), sealed with a clear cover foil (Thermo 
Scientific), and analyzed in a CFX96 Touch thermal cycler (BioRad). 
 
The following program was used for the qPCR: 
 
Table 7: qPCR program  
Step Temperature (°C) Time Number of Cycles 
Initial denaturation 95 8 minutes 1 
Denaturation 95 20 seconds 
40 
Annealing 58 35 seconds 
Extension 72 20 seconds,  
data acquisition 
Final Extension 72 2 minutes 1 
Melt Curve 60 – 95, steps of 0,5  4 seconds each step 1 
 
For the statistic, we used first a F-Test to decide if we can perform an unpaired T-Test or have to use 
the Mann-Whitney test.  
The F-Test calculates if the variants were significant different. Samples with high variants lead to 
smaller unjustified p-values. Therefore, the unpaired T-Test was only performed when the F-Test was 
negative. In the case of a positive F-Test the Mann-Whitney test was used 
Statistical values were not calculated for sample numbers <=2.  
For the subpopulations of CD4+ cells, we calculated the significance with a One-way Anova followed 
by the Bonferroni correction as a post-test because 4 independent groups were analyzed. 
 
 
2.8! Flow cytometry 
 
With flow cytometry, different cell populations can be analyzed by labeling cells with antibodies (Ab) 
carry different fluorochromes. With different lasers and filters fluorophores can be excited and they emit 
light of certain wave-length. With the specificity of the antibodies and the attached fluorochromes 
different cell populations out of a cell suspension can be sorted and analyzed with a flow cytometer. The 
Ab can be directly attached to a fluorophore or a labeled secondary Ab can be used to bind the primary 
Ab. For the staining of the cells, many different colors and antigens can be used. Therefore, many 
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different cells in a solution can be distinguished and counted. Also, specific cells can be sorted for later 
analysis.  
 
Filtered and separated cells were centrifuge at 400 x g for 10 min and resuspended in 8°C cold flow 
cytometry buffer. For every staining 1 x 106 cells were transferred in a reaction tube and centrifuged. 
Supernatant was discarded, and cells resuspended in cold flow cytometry buffer with primary Ab. 
Solutions with labeled Ab were kept out of light if possible. After 15 min incubation in the refrigerator 
cells were again centrifuged at 400 g for 10 min to separate cells from unbound antibodies. Supernatant 
with antibodies was discarded and cells resuspended in flow cytometry buffer with labeled secondary 
Ab if needed. Cells were incubated for 10 min and again centrifuged at 400 x g for 10 min. Supernatant 
was discarded and the cell pellet resuspended in flow cytometry buffer with DAPI or PI to stain dead 
cells. Stained cells were kept on ice and in the dark until they were analyzed and if required sorted on 
the flow cytometer (LSR II (BD), Aria II (BD), MACSQuant (Miltenyi), CANTO II (BD). For the 
compensation OneComp eBeads (eBioscinece, 01–1111-42) were incubated with every single antibody 
and measured. Furthermore, unstained cells were used to control autofluorescence. The sorted cells were 
collected in reaction tubes with qPCR lysis puffer for later experiments. Analyzation of flow cytometry 
data were performed using FlowJo. Antibodies used for the flow cytometry are listed in the Table 8.  
 
 
Table 8: Flow cytometry antibodies for the lymphoid and myeloid staining 
 
antigene fluorochromes dilution company product number 
lymphoid CD45.2 APC eF780 100 ebioscience 4302540 
  B220 PE-Cy7 500 ebioscience RA-6B2 
  CD3 APC  200 ebioscience 145-2C11 
  CD4 PE  200 ebioscience GK1,5 
  CD8 PE-Cy5 400 ebioscience ebioH 35-17.2 
 
          
myeloid CD45 PE-Cy7 700 ebioscience 30-F11 
  CD11b AmCyan 400 BD  M1/70 
  CD11c APC-Cy7 100 BD HL3 
  SiglecF PE 200 BD E50-2440 
  Ly6G APC  200 ebioscience 1A8 
  F4/80 PE-Cy5 300 ebioscience BM8 
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3! Results 
 
3.1! Neuropilin-2 as a prognostic marker in PDAC 
 
To analyze the potential of Neuropilin-2 as a prognostic marker with and without its interaction partner 
VEGF-C in PDAC, a co-staining was performed on a cohort and graded.  
The score was correlated with the survival of the patients. The tissues for this analysis were combined 
previously for a different study and published in Nature (Pérez-Mancera et al., 2012). All patients were 
operated, and the details of the cohort were summarized in Table 9. 
 
Table 9: Summary of TMA properties.  
  
 
To confirm the quality of the cohort we correlated a high and low Union for International Cancer Control 
(UICC) score with the overall survival. The UICC scores shows the progression of the cancer and a 
higher score is indicating a further progressed cancer. We divided the samples into two groups: <= IIA 
and >= IIB and plotted them using a Kaplan-Meier curve. As expected, a higher UICC score correlates 
with a poor prognosis. The cancer specific survival dropped from 559 days for <= IIA score to 442 days 
with a score >= IIB (Fig. 10).  
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Fig. 10: UICC dependent survival. A lower UICC score correlated with a longer survival. (statistical significance 
was calculated by Log-rank Test) 
 
To analyze the potential of NRP2 and VEGF-C as a prognostic marker in PDACs, the samples were 
scored depending on the expression of the respective protein in all tumor cells and divided into a high 
and low score group. 
The intensity (1 to 3) of the staining, the percent of stained tumor cells (0, 1<25%, 2<50%,3<75%, 
4>75%) and the co-expression (0 to 1.0 in 0,1 steps) was graded from two separate researchers (one 
pathologist) and the median was formed. Examples for the grading are shown in Fig. 11. 
For the analysis, the intensity and percent score were added. For the statistic, the data was divided into 
two groups: high: NRP2>=6; VEGF-C>=7; low: NRP2<6; VEGF-C<7 and a co-localization score 
>=0,8. Due to the more intense color at the VEGF-C staining the border between the upper and lower 
group was set higher than for the NRP2 staining. 
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Fig. 11: Grading of NRP2 and VEGF-C intensity and amount of tumor cells in PDAC. Staining of PDAC against 
NRP2 in brown and VEGF-C in red. In a) are all the tumor cells stained brown but not red, therefore the NRP2 
score was 4 for the percentage. The intensity of the stain was scored with 2. The score for VEGF-C was 0 for 
intensity/percentage because no red stain was visible. Thus, the score for the co-localization was 0. The first 
number is the intensity, the second the percentage. In summary, the score was: NRP2 2;2, VEGF-C 0;0, co-lo = 
0. b) got a score of NRP2 2;4, VEGF-C 2;4, co-lo = 0,80. c) NRP2 2;4, VEGF-C 3;4, co-lo = 1 and d) NRP2 3;3, 
VEGF-C 3;2, co-lo = 0,20. 
 
First, we analyzed the prognostic potential of NRP2 and VEGF-C in PDAC separate and correlated the 
low and high groups with the overall survival. So far, a high NRP2 expression in certain cancers was 
associated with a poor prognosis. But in our PDAC study a high NRP2 score correlates with a significant 
longer survival (538 days) compared with a lower NRP2 score (403 days) (p = 0,0449) (Fig. 12a).  
Many studies correlated high VEGF-C expression with the survival rate in various cancers and yielded 
conflicting results. We analyzed a high score of VEGF-C in PDACs but found no connection between 
the expression and the survival (Fig. 12b). 
 
NRP2 and VEGF-C are binding partners (Prud'homme and Glinka, 2012) and due to the fact that high 
NRP2 expression in PDACs is associated with a longer survival, we analyzed if a co-expression of 
NRP2 and VEGF-C in tumor cells showed a correlation between the overall survival (Fig. 12c). In 
contrast to the results with NRP2 alone, a co-expression with VEGF-C has no correlation with the 
survival rate. 
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Fig. 12: Correlation of NRP2 and VEGF-C on survival of PDAC patients: a) high NRP2 expression correlated 
with a significant longer survival (p = 0,0449). VEGF-C expression (b) and the co-expression of NRP2 and VEGF-
C (c) showed no correlation on the survival of PDAC patients (VEGF-C p = 0,8668, co-expression p = 0,2293). 
(statistical significance was calculated by Log-rank Test). 
 
Forty five percent of patients were treated after surgery in accordance with the German guidelines for 
pancreatic cancer and our previous work linked NRP2 expression to therapy resistance in bladder and 
prostate cancer (Keck et al., 2015; Muders et al., 2009b). Therefore, we separated the patients with a 
post operation therapy from the ones without a treatment and correlated the NRP2 score with the survival 
(Fig. 13). NRP2 expression had no effect on the overall survival in patients without treatment. In 
contrast, a high NRP2 expression in patients with adjunctive therapy after surgery was associated with 
a longer survival (649 days to 442 days), but only with a statistical trend with a p value of 0,075.  
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Fig. 13: NRP2 and adjuvant dependent survival. a) Higher expression of NRP2 after treatment correlated with a 
longer survival (p = 0,075). b) In the group without post operation treatment the NRP2 expression had no effect. 
(statistical significance was calculated by Log-rank Test). 
 
Tumor cells in addition to other cells surrounding the cancer were stained in the PDAC (Fig. 14). 
Pathologists identified among these cells macrophages and we verified the statement with a double 
staining against NRP2 and PgM1, a common macrophage marker in humans (Fig. 14).  
 
Macrophages in and around a tumor are a special population of cells called tumor associated 
macrophages (TAMs). The high expression of NRP2 in TAMs drew our attention and we further 
investigated the role of NRP2 in immune cells during cancer progression. Furthermore, we confirmed 
NRP2 expression in macrophages in other human tissues, including the paranasal sinus (Fig. 14d). 
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Fig. 14: NRP2 expression in macrophages. a) and b) showed a double staining for PgM1 in red and NRP2 in 
brown. The arrows indicated cells with a co-expression close to tumor cells. In c) were macrophages in close 
proximity to the tumor expressing high amount of NRP2. d) showed the paranasal sinus stained against NRP2. 
The arrows point out NRP2 expressing macrophages. (scale bar = 50 !m)  
 
 
3.2! Effects of NRP2 deficiency on macrophages and role of NRP2 in 
immune cells during tumor progression in mice 
 
3.2.1! Effects of NRP2 depletion on macrophages 
 
In addition to others, we showed that NRP2 was expressed in macrophages in human tissue and in mice, 
but functions of NRP2 were still unknown. Mouse models have many advantages for studying biological 
questions compared to in vitro experiments due to the option of conditional and full knock-outs of certain 
genes/proteins. Furthermore, knock-out cells can be isolated and studied in vitro. That is why we used 
mice for our analysis. 
First, we questioned if a knock-out of NRP2 affects the differentiation and polarization towards M1- and 
M2-macrophages. For that we isolated monocytes from wt and LysM:cre-NRP2Loxp/LoxP mice. In the 
LysM:cre-NRP2LoxP/LoxP mice NRP2 was cut out by the cre-recombinase in macrophages.  
Monocytes were isolated, cultured and differentiated followed by a stimulation towards M1- or 
M2-macrophages. First, the expression and the knock-out efficiency of the unstimulated and stimulated 
a) b)
c) d)
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cells were analyzed by qPCR using primers against both isoforms of NRP2, NRP2a and NRP2b. In the 
unstimulated and stimulated conditions, the knock-out efficiency was above 90 %. Also, the expression 
of NRP2a and NRP2b was increased after stimulation with LPS towards M1- and IL-4 towards 
M2-macrophages. Both isoforms were more than 2,5 x increased after LPS treatment, whereas after IL-4 
treatment the increase was about 1,5 x (Fig. 15). In accordance with the literature our data showed no 
NRP2 expression in monocytes (not shown) (Ji et al., 2009). In summary, it was clear that macrophages 
increase their NRP2 expression during the differentiation and polarization towards M1- and 
M2-macrophages and the knock-out of NRP2 was efficient. 
 
 
Fig. 15: NRP2a/b expression in M1- and M2-macrophages. a) NRP2a expression was significantly increased 
during the polarization of M' to M1-macrophages. The knock-out efficiency was over 95 %. (M1: NRP2a 
p = 0,0017). b) NRP2b showed the same results as for NRP2a, but the F-Test was positive. Therefore, the Mann-
Whitney T-Test was performed (M1: NRP2b p = 0,0278). c) and d) showed the NRP2a/b expression of M2 and the 
knock-out efficiency (95 %). Both isoforms were increased by nearly 1,5 x but both not significantly (M2:NRP2a 
p = 0,06, NRP2b p = 0,2331) (n = M1 5wt/2ko; M2 9wt/5ko) 
 
Next, we analyzed if the polarization towards M1- and M2-macrophages was impaired in the knock-out 
condition by checking certain maker genes. For M1-macrophages we used iNOS and IL-1#. 
Unstimulated macrophages do not express these genes or only to a very low extent. During the 
polarization towards an M1-character the expression of marker genes increases (Fig. 16a&b). In both 
conditions, knock-out and wildtype (wt), the M1 marker genes were similarly upregulated (Fig. 16a&b). 
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Additionally, we analyzed the M1 maker genes TNF-& and Ship and they showed again an increase 
after LPS treatment, but no difference between the wt and ko cells.  
Next, we analyzed the M2-macrophages by checking the M2 marker genes Arg1 and Ym1. Again, after 
the stimulation with IL-4 the expression increased, and no significant difference was detected (Fig. 
16d&e). To confirm these results, we analyzed the additional M2 marker IL-10 and Fizz1 and they also 
showed an increase after IL-4 treatment but no difference between the wt and ko cells (data not shown). 
Because TAMs can induce angiogenesis by secreting VEGF-A, we checked for the expression of 
VEGF-A, which is important for sustained tumor growth (Carmeliet, 2005). The expression of VEGF-A 
decreases during the polarization towards M1-macrophages by more than 80 %, but to a lesser extent in 
the knock-out condition (Fig. 16c). For M2-macrophages, neither the stimulation with IL-4 in wt cells 
nor in the NRP2 knock-out cells had an influence on the VEGF-A expression (Fig. 16f). 
In summary, the macrophages polarized towards M1- and M2-macrophages independent of NRP2 
expression.  
 
 
Fig. 16: Comparison of marker genes and VEGF-A expression of M1- and M2-macrophages in wt and NRP2 ko 
cells. a), b) and c) were M1-macrophages. a) iNOS and b) IL-1# were expressed after LPS stimulation in 
M1-macrophages in both wt and ko cells. c) VEGF-A was significantly reduced in M1-macrophages compared to 
M' (p < 0,0001). The reduction was less in the ko samples. NRP2 deficient M1-macrophages express more 
VEGF-A than the wt cells. d) Ym1 and e) Arg1 were expressed after IL-4 stimulation and no difference were 
detected between wt and ko cells. f) No regulation of VEGF-A was detected between the wt and ko cell as well as 
between treated and untreated cells. (n = M1 5wt/2ko; M2 9wt/5ko) 
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3.2.2! Role of a conditional knock-out of NRP2 in immune cells during tumor progression 
 
To investigate the role of NRP2 in macrophages during the progression of tumors we used 
LysM:cre-NRP2LoxP/LoxP mice. With the Vav:cre-NRP2LoxP/LoxP mice hematopoietic stem cells were 
targeted, which results in an early knock-out of NRP2 in the immune cells. With this model, we can 
analyze the effect of NRP2 knock-out in all immune cells during cancer progression. Both mouse lines 
showed normal behavior, were normal in size and breeding ability. In both conditional knock-out 
models, cells of the blood system were targeted. Due to the early and broad knock-out in the 
Vav:cre-NRP2LoxP/LoxP mice we examined their blood and compared it to the wt. We performed a 
complete blood count (CBC) and differential blood count (DBC). No changes were detected in either 
females or males and exemplary neutrophils, eosinophils, basophils, monocytes, red and white blood 
cells and hemoglobin were shown (Fig. 17). 
 
 
Fig. 17: Analysis of blood from wt and Vav:cre-NRP2LoxP/LoxP mice. No difference was detected in red blood cells 
a) or white bloods b) nor in the hemoglobin level c). Cells of the immune system, in detail neutrophils d), 
lymphocytes e), monocytes f) and eosinophils g) were analyzed and no difference between the conditional 
knock-out and wt mice were detected. (n = 5wt/5Vav:cre-NRP2LoxP/LoxP) 
 
Previous work showed that a full knock-out of NRP2 led to trabecular bone loss in mice and changes 
the cell numbers of osteoclasts and osteoblasts (Verlinden et al., 2013). Osteoclasts originate from the 
hematopoietic lineage (Matsuo and Irie, 2008) and the Vav promotor is active in the hematopoietic stem 
cells. An impaired bone formation can have effects on the immune cells which originate from the bone 
marrow. Therefore, we checked bones for volume, trabecular thickness and mineral density and no 
difference between the Vav:cre-NRP2LoxP/LoxP and the wt was detected (Fig. 18). 
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Fig. 18: Analysis of the bone of wt and Vav:cre-NRP2LoxP/LoxP mice. No difference was detected in the total bone 
volume a), the trabecular thickness b) or the bone mineral density c) between the wt and the Vav:cre-NRP2LoxP/LoxP. 
(n = 4wt/6Vav:cre-NRP2LoxP/LoxP) 
 
In summary, we found no phenotype in the conditional knock-out, change in the blood system or bones 
of Vav:cre-NRP2LoxP/LoxP mice.  
To study the role of NRP2 in the immune system during cancer progression we injected Lewis Lung 
Carcinoma (LLC) cells subcutaneously in the back of wt, LysM:cre-NRP2LoxP/LoxP and 
Vav:cre-NRP2LoxP/LoxP mice. First, we used the LysM:cre-NRP2LoxP/LoxP mice for the experiment because 
the LsyM promotor is mostly active in activated macrophages. Therefore, this model offered the 
opportunity to study the NRP2 in macrophages during the experiment. No difference in the tumor 
volume was detected in two separate experiments compared to the wt condition (Fig. 19).  
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Fig. 19: LLC tumor growths in wt and LysM:cre-NRP2LoxP/LoxP mice. a) showed the tumor growths of 
subcutaneously injected LLC cells. The tumor volume was plotted as function of time. No difference was detected 
between the wt and the LysM:cre-NRP2LoxP/LoxP mice (n = 9wt/7LysM:cre-NRP2LoxP/LoxP). b) showed the repeated 
experiment and again no difference was detected (n = 8wt/7LysM:cre-NRP2LoxP/LoxP). 
 
Next, we used the Vav:cre-NRP2LoxP/LoxP mice in which the cre-recombinase leads to a conditional 
knock-out of NRP2 in the hematopoietic stem cells. Therefore, all immune cells were targeted. The 
tumor volume in the first experiment was increased in the Vav:cre-NRP2LoxP/LoxP condition, but not 
significantly (Fig. 20a). In contrast, in the second experiment the tumor volume in the conditional 
knock-out was slightly decreased (Fig. 20b). The third experiment showed tumor growth for a longer 
time period but the volume of the tumor in the Vav:cre-NRP2LoxP/LoxP condition was again only slightly 
increased (Fig. 20c).  
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Fig. 20: LLC tumor growths in wt and Vav:cre-NRP2LoxP/LoxP mice. a) In the first experiment the tumor volume in 
Vav:cre-NRP2LoxP/LoxP mice increased slightly faster than in wt, but not significantly. 
(n = 6wt/7Vav:cre-NRP2LoxP/LoxP). b) showed no difference in the tumor volume in both mice lines 
(n = 17wt/9Vav:cre-NRP2LoxP/LoxP). c) In the third experiment the tumor grew for a longer time period and was 
slightly increased in the Vav:cre-NRP2LoxP/LoxP mice (n = 8wt/6Vav:cre-NRP2LoxP/LoxP). 
 
The tumors grew fast thus we did not follow the growth for more than 21 days. Therefore, we tried the 
same set up with 500.000 cells and 350.000 cells, but no differences were detected there. With 250.000 
cells, most tumors did not develop (data not shown).  
Even tumors that had grown similarly in size can be heterogeneous regarding to cell composition, for 
example, immune cells and vessel development.  
Vessels are important for the supply of nutrients for cells to keep up their metabolism. Without the 
steady supply of nutrients especially cells with a high turn-over like tumor cells starve resulting in cell 
death called necrosis. 
Therefore, we stained the paraffin embedded LLC tumors with the vessel marker CD31, and 3 separate 
scientists scored blinded the number of vessels in the tumor. The score varies between 0-4 with 4 
indicating the highest score. The mean score for the wt condition was at 1,5. Significantly lower was the 
score for LysM:cre-NRP2LoxP/LoxP (mean = 0,9, p = 0,0228) and Vav:cre-NRP2LoxP/LoxP (mean = 0,74, 
p = 0,0094) (Fig. 21). 
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Fig. 21: CD31 staining of LLC tumors in wt, LysM:cre-NRP2LoxP/LoxP and Vav:cre-NRP2LoxP/LoxP mice. a) Blinded 
scoring of the CD31 staining in wt, LysM:cre-NRP2LoxP/LoxP and Vav:cre-NRP2LoxP/LoxP mice. The mean score from 
wt mice was 1,5. Significantly reduced was the score for LysM:cre-NRP2LoxP/LoxP mice (mean = 0,9, p = 0,0288) 
and Vav:cre-NRP2LoxP/LoxP mice (mean = 0,74, p = 0,0094). b) shows a sample picture of a LLC tumor in wt and 
c) for LysM:cre-NRP2LoxP/LoxP mice.(scale bar = 50 !m) 
 
From a different experiment, we collected frozen tumor tissue from wt and LysM:cre-NRP2LoxP/LoxP 
mice. We performed a fluorescence staining with a different CD31 antibody and used the fluorescence 
intensity for the analysis. Again, the CD31 staining was highly reduced in the conditional knock-out 
sample (p = 0,0571) (Fig. 22).  
 
 
Fig. 22: Fluorescence staining against CD31 of LLC tumors in wt and LysM:cre-NRP2LoxP/LoxP mice. a) 
Quantification of fluorescence intensity of the stained slides. The intensity was reduced in the 
LysM:cre-NRP2LoxP/LoxP mice (p = 0,0571). b) shows a sample picture of a LLC tumor in wt mice. The red color 
marked the CD31 stain and blue was the nucleus stain DAPI. c) was a stained tumor slide from 
LysM:cre-NRP2LoxP/LoxP  mice. (scale bar = 100 !m) 
 
In the mouse models, NRP2 was cut out in macrophages and other immune cells. Macrophages are a 
main cell type in LLC tumors (C. Lee et al., 2017). Therefore, we performed a CD206 staining to analyze 
the M2-macrophages in the tumor. 
We compared the fluorescence intensity from LysM:cre-NRP2LoxP/LoxP mice with wt mice and found no 
difference (Fig. 23a). Also, all cells and CD206 positive cells were counted in four random areas of each 
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slide and wt compared to the conditional knock-out. Again, no difference was detected (Fig. 23b). 
Around half of the cells in the LLC tumors were CD206 positive (Fig. 23b&c). 
 
 
Fig. 23: CD206 staining on LLC tumors. a) The fluorescence intensity was measured and tumors from wt and 
LysM-NRP2LoxP/LoxP were compared. No difference was detected. In b) cells were counted and again no difference 
was detected between the wt and LysM:cre-NRP2LoxP/LoxP mice. More than 45 % of the cells in the tumor were 
CD206 positive in both conditions. c) Fluorescence staining against CD206 in red with a nucleus staining (DAPI, 
blue). More than 45 % of cells were stained red. (scale bar = 100 !m) 
 
A decrease in vessels formation can have an influence in the necrotic areas of a tumor. Slightly more 
necrosis was detected in tumors from LysM:cre-NRP2LoxP/LoxP and Vav:cre-NRP2LoxP/LoxP (Fig. 24). 
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Fig. 24: Analysis of necrotic areas of LLC tumors. a) Quantification of necrotic areas from wt, 
LysM:cre-NRP2LoxP/LoxP and Vav:cre-NRP2LoxP/LoxP. More necrosis was detected in the conditional ko situations. 
b) H&E stained tumor slide. Encircled is the necrotic area. (scale bar = 100 !m)  
 
Tumors from wt and Vav:cre-NRP2LoxP/LoxP were lysed, and macrophages, neutrophils and T cells were 
sorted. The cells were checked for NRP2 expression by qPCR. Neutrophils express 2 x and T cells 4 x 
as much NRP2 mRNA as macrophages Fig. 25a). Next, the knock-out efficiency in macrophages was 
verified and the efficiency was 81 % Fig. 25b). 
 
 
Fig. 25: Gene expression of sorted cells out of LLC tumors. a) showed the expression of macrophages, neutrophils 
and T cells. Neutrophils express 2 x and T cells 4 x as much NRP2 mRNA as macrophages. b) Sorted macrophages 
out of LLC tumor from wt and Vav:cre-NRP2LoxP/LoxP  were analyzed for NRP2 expression. NRP2 expression was 
89 % reduced in the Vav:cre-NRP2LoxP/LoxP condition. (n = 1wt/1Vav:cre-NRP2LoxP/LoxP) 
 
 
The lungs of the mice were checked for metastasis, but all lungs were found negative for tumors. 
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3.3! Role of NRP2 knock-out in immune cells during inflammation 
 
3.3.1! Mild allergic model of the lung  
 
NRP2 is expressed in different immune cells and therefore could have different functions ((Fig. 25a), as 
reviewed in (Schellenburg et al., 2017)). To study the effect of a NRP2 knock-out in immune cells, we 
performed a mild allergic inflammation model of the lung of Vav:cre-NRP2LoxP/LoxP and wt mice. During 
that model, many immune cells were activated and an immune response was triggered (Toussaint et al., 
2013). Because of the broad knock-out in the immune system the Vav:cre-NRP2LoxP/LoxP were used for 
the experiment.  
 
 
Fig. 26: PAS-staining of lungs from Ova challenged mice. a) showed the quantification in percent of PAS positive 
bronchia in lungs of wt and Vav:cre-NRP2LoxP/LoxP mice and no difference was detected. Around 20 % of the 
bronchia were PAS positive. b) & c) Percentage of PAS positive cells in the bronchia were elucidated. Around 
20 % of the cells in PAS positive bronchia (b) and 5 % of total cells (c) in bronchia were stained. Both 
quantifications showed no significant difference between the wt and the Vav:cre-NRP2 condition. d) PAS staining 
of the lung. Arrows showed PAS positive bronchia (scale bar = 200 !m). e) PAS positive cells in a bronchius. 
Arrows pointed out two PAS positive cells (scale bar = 50 !m). 
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PAS-staining of the lung and the analysis of the bronchoalveolar lavage fluid (BALF) are used as 
indicators for the severity of the inflammation. 
The PAS-staining was analyzed by evaluating the percentage of PAS positive bronchia and PAS positive 
cells. No difference in the staining of the bronchia nor in the cells between wt and Vav:cre-NRP2LoxP/LoxP 
mice was detected. 
 
Analysis of the BALF is a more sensitive method to evaluate the severity of the inflammation of the 
lung. The BALF contained immune cells, which can be distinguished by flow cytometry. Changes in 
the population of immune cells can be detected through a percentagewise separation of the cells.  
For the analysis of the BALF, we washed the lungs, isolated the cells and analyzed the cell suspension 
by flow cytometry. We performed the experiment twice and combined these two independent 
experiments in the following figures. First, we looked at the total leukocytes. They were reduced, but 
not significantly in the conditional knock-out samples. 
  
Fig. 27: Total CD45+ cells out of BALF from wt and Vav:cre-NRP2LoxP/LoxP mice after Ova challenge. The amount 
of CD45+ cells in the BALF from wt (mean = 44417 cells) were reduced in Vav:cre-NRP2LoxP/LoxP (mean = 24375) 
(n = 6wt/4Vav:cre-NRP2LoxP/LoxP) 
 
Next, we analyzed the myeloid cells for their percentage occurrence. In healthy lungs are alveolar 
macrophages (AMs) present named after their occurrence in the alveoli. Also, polymorphonuclear 
leukocytes (PMNs) referred as neutrophils migrated in the lung during an inflammation. Both 
populations were slightly increased, but inconspicuous (Fig. 28). Eosinophils are commonly used as 
indicators for allergic diseases, infections and cancers. During the mild allergic inflammation in the lung 
the eosinophil population was significantly reduced in the conditional knock-out (p = 0,0381) (Fig. 29). 
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Fig. 28: Percentage of AMs and (PMNs) in BALF from wt and Vav:cre-NRP2LoxP/LoxP mice after Ova challenge. 
AMs (a) and PMNs (b) were slightly increase in the BALF of Vav:cre-NRP2LoxP/LoxP mice. 
 
 
Fig. 29: Percentage of eosinophils in BALF from wt and Vav:cre-NRP2LoxP/LoxP mice after Ova challenge. 
Eosinophils were significant reduced in the BALF of Vav:cre-NRP2LoxP/LoxP mice. 
(n = 6wt/4Vav:cre-NRP2LoxP/LoxP, p = 0,0381) 
 
Furthermore, we analyzed B and T cells. B cells are known for their function to produce antibodies, but 
can also have regulatory functions during inflammation (Braza et al., 2014). T cells have a diverse 
function depending on the subpopulation. Their function is indisputable as an important mediator during 
an inflammation. Whereas there was no significant regulation of B cells in the BALF, the T cells 
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significantly decreased from 23 % to 11 % in Vav:cre-NRP2LoxP/LoxP  (p-value of 0,0381). We examined 
the T cells further by dividing the population into CD4+ and CD8+ T cells. CD4+ cells are involved in 
induction and restraint of many immunological functions, whereas CD8+ cells function as killer cells 
and destroy infectious particles. 
The CD4+ cells were reduced in the conditional knock-out from 16,2 % to 7,3 % with a statistical value 
of 0,1087. The CD8+ cells were significantly reduced from 5,4 % to 1,4 % with a p value of 0,019. 
 
Fig. 30: Percentage of B and T cells in BALF from wt and Vav:cre-NRP2LoxP/LoxP mice after Ova challenge. a) No 
regulation of B cells in BALF was detected. b) T cells were significantly reduced in the BALF from 
Vav:cre-NRP2LoxP/LoxP mice.  
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Fig. 31: Percentage of CD4+ and CD8+ T cells in BALF from wt and Vav:cre-NRP2LoxP/LoxP mice after Ova 
challenge. a) CD4+ cells were reduced in the Vav:cre-NRP2 condition and showed a statistical trend with a p 
value of 0,1. b) CD8+ cells were significantly reduced in the BALF of Vav:cre-NRP2LoxP/LoxP mice (p = 0,019). 
(n = 6wt/4Vav:cre-NRP2LoxP/LoxP) 
 
 
3.3.2! Analysis of NRP2 deficient T cells 
 
It is known that T cells express NRP2, but the functions are mostly unknown at this point. In our model 
of the mild allergic inflammation, we found that NRP2 deficiency led to a reduction of T cells. 
Therefore, we investigated further what effect a knock-out of NRP2 had in CD4+ and CD8+ T cell 
populations. 
First, we compared naïve CD4+ T cells out of LN and spleen with CD8+ T cells isolated out of LN and 
spleen. The CD8+ cells have more than 9 x as much RNA for NRP2 than the naïve CD4+ T cells (Fig. 
32).  
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Fig. 32: NRP2 expression of CD4+ and CD8+ T cells. The expression of NRP2 was 9 x higher in CD8+ cells 
compared to CD4+ cells with a p value of p<0,0001. (n = 3/3) 
 
Next, we analyzed the NRP2 deficient CD8+ cells. The knock-out efficiency was more than 90 %. 
Additionally, we checked the pro-inflammatory genes IL-2, IFN" and TGF#, which are especially 
important in CD8+ T cells. All these genes were reduced, but not significantly (Fig. 33). 
 
 
Fig. 33: Gene expression in wt and NRP2 ko CD8+ cells. a) NRP2 was over 90 % reduced in the ko condition. 
IFN" (b), IL-2 (c) and TGF# (d) were all reduced but not significantly. (n = 3wt/6ko) 
Furthermore, we analyzed different subpopulation of the CD4+ T cells which are involved in different 
processes. We analyzed the four major populations: Th1, Th2, Th17 and Treg cells. Th1 cells had nearly 
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no NRP2 expression, Tregs significantly more. Th2 cells express 9 x as much NRP2 RNA compared to 
Treg cells. The highest expression was in Th17 cells with more than twice as much compared to Th2 
cells.  
 
Fig. 34: NRP2 expression in different T helper populations. Th1 had no NRP2 expression. Treg cells express NRP2 
at a low level. Th2 cells express 9 x more NRP2 RNA compared to Treg cells and Th17 had the highest expression 
with more than 2 x the expression of Th2 cells. (n = 3/3/3/3) 
 
Next, we analyzed certain genes in NRP2 knock-out subpopulations. First, we checked the Th1 cells, 
which expressed no NRP2. Two marker genes for Th1 cells are IL-2 and IFN". IL-2 is important for the 
proliferation of T cells, while IFN" is a major pro-inflammatory cytokine. Both were expressed after 
cultivation, but no regulation was found between wt and ko cells. VEGF-A plays a role in the 
polarization of Th1 (Mor et al., 2004). Thus, we checked for VEGF-A but found no regulation of the 
expression (Fig. 35).  
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Fig. 35: Gene expression in wt and ko Th1 cells. No regulation was detected in the expression of IL-2 a), IFN" b) 
and VEGF-A c). (n = 3wt/3ko) 
 
The knock-out efficiency in Th2 cells for NRP2 was at 80 % (Fig. 36a). Furthermore, we analyzed the 
regulation of NRP2 deficiency in Th2 cells on certain genes, which are important during an immune 
response. No effect was detected on the expression of TGF-# (Fig. 36b) and IL-17 (Fig. 36c). The 
expression of IFN" was reduced by 33% but not significantly (Fig. 36d). IL-4 is important for the 
differentiation and proliferation of Th2 cells. The NRP2 ko led to a 50 % reduction of the expression of 
IL-4 but showed no significance (Fig. 37a). 
 
 
Fig. 36: Expression of NRP2, IFN", IL-17 and TGF-# in NRP2 deficient Th2 cells. a) NRP2 was 80 % reduced in 
the ko cells. (n = 3wt/3ko). No regulation in TGF-# b) (n = 3wt/3ko) and IL-17 c) (n = 5wt/6ko) was detected. d) 
IFN" was reduced in the ko cells but not significantly. (n = 5wt/6ko) 
 
Furthermore, we analyzed cytokines expressed by Th2 cells during an immune response, which are also 
important as pro-inflammatory mediators for allergic disease, IL-5 and IL-13. Both were significantly 
upregulated in NRP2 deficient Th2 cells (Fig. 37b&d). Not only pro-inflammatory cytokines were 
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upregulated. Also, IL-10, which is known for its anti-inflammatory effects, is significantly increased 
(Fig. 37c). 
 
Fig. 37: Expression of IL-4, IL-5, IL-10 and IL-13 in NRP2 deficient Th2 cells. a) IL-4 expression was reduced by 
50 %, but not significantly (p = 0,0742, n = 3wt/3ko). The expression of IL-5 b) was significantly upregulated by 
a factor of 2,6 x (p = 0,0013, n = 5wt/6ko), IL-10 c) by 2,3 (p = 0,0273, n = 3wt/3ko) and IL-13 d) by 2,1 x 
(p = 0,0033, n = 5wt/6ko) 
 
Furthermore, we analyzed the expression of interaction partners of NRP2: Sema3F, VEGF-C and 
VEGF-A. No significant regulation was detected but the expression of VEGF-A was doubled (2,2 x) in 
the ko situation. 
 
 
Fig. 38: Expression of NRP2 binding partners in NRP2 deficient Th2 cells. a) VEGF-A was upregulated by 2,2 x 
in the NRP2 deficient Th2 cells (p = 0,0993). No regulation was detected in the expression of VEGF-C b) or 
Sema3F c). (n = 3wt/3ko) 
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Lastly, we analyzed NRP2 deficient Th17 cells. First, we checked the knock-out efficiency which 
resulted in a reduction of 85 %. Then, we analyzed two major marker genes for Th17 cells, IL-17 and 
IFN". Both were expressed in both wt and ko cells without any regulation. IL-5 and IL-13 was 
upregulated in Th2 cells, so we checked for any differences in Th17. We found no regulation for IL-5 
but a reduction of IL-13 by 46 % which was not significant. Furthermore, we analyzed VEGF-A 
expression and found no regulation (Fig. 39).  
 
Fig. 39: Gene expression of NRP2 deficient Th17 cells. a) NRP2 expression was 85 % reduced in the NRP2 ko 
Th17 cells (n = 3wt/3ko). IL-17 b) (n = 6wt/5ko), IFN" c) (n = 7wt/5ko), IL-5 d) (n = 3wt/3ko) and VEGF-A f) 
(n = 3wt/3ko) showed no regulation in NRP2 deficient Th17 cells. IL-13 expression was reduced by 46 % but not 
significantly (n = 5wt/4ko). 
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4! Discussion 
 
 
4.1! Neuropilin-2 as a prognostic marker in PDAC 
 
In contrast to our hypothesis that NRP2 expression correlates with a poor prognosis in PDAC, we found 
out that a higher expression of NRP2 is associated with a significantly longer cancer specific survival. 
These results seems to stand in contrast to data from the literature where we and others showed that a 
high expression of NRP2 in breast and bladder cancer is linked to a poor prognosis (Keck et al., 2015; 
Yasuoka et al., 2009). Proteins in different cells types can have varying functions. Therefore, the 
prognostic potential of NRP2 could vary between cancer types. But Dallas et al. suggests that the 
function and prognostic potential of NRP2 in pancreatic cancer data is in line with other cancers. They 
performed a subcutaneous model with PDAC cells and found out that a stable knock-down of NRP2 
leads to a reduced tumor growth. Furthermore, they performed an orthotopic model with a pancreatic 
cancer cell line and again, cells lacking NRP2 showed a reduced tumor growth (Dallas et al., 2008). The 
reduced tumor growth was not due to an impaired proliferation, but could be because of secondary 
effects in the vasculature (Dallas et al., 2008). Vascularization is an essential progress for cancer 
progression and can be used in several tumors as a prognostic marker (Sternfeld et al., 1999). In fact, 
the NRP2/VEGFs axis is likely to be involved or responsible for the vascularization in many cancers 
(Kärpänen et al., 2006; Prud'homme and Glinka, 2012). Especially VEGF-C is known for its function 
in lymphangiogenesis and VEGF-A for angiogenesis. NRP2 is known to enhance both processes (Caunt 
et al., 2008; Koch and Claesson-Welsh, 2012; Moriarty et al., 2016; Xu et al., 2010). The vascularization 
of tumor tissue is not only important for the supply of nutrients, but also for the spreading of tumor cells 
(Hanahan and Weinberg, 2011; Perou et al., 2000). 
Furthermore, NRP2 expression is associated with an increase of metastasis. Metastasis is the leading 
cause of death in cancer patients, leading to increased attention of researchers (Fidler and Balch, 1987; 
Sporn, 1996). NRP2 on tumor cells interacts with endothelial cells through "5 integrin. A blockade of 
NRP2 inhibits the interaction, which leads to an impaired tumor cell adhesion to the endothelium. This 
process is important for the tumor cell extravasation, which is a critical step for the metastasis (Y. Cao 
et al., 2013). All these data support the pro-tumorigenic functions of NRP2 and gives indications of 
important roles of NRP2 during cancer progression. Cao et al. also supported this data with a correlation 
of NRP2 expression with the survival in PDACs. They showed that patients with a high mRNA 
expression of NRP2 have a significantly shorter survival rate (Y. Cao et al., 2013). In summary, all these 
data are strongly suggesting that a high expression of NRP2 leads to faster tumor progression and 
metastasis, and therefore to a quicker cancer related death. We showed that a high NRP2 expression 
correlates with a longer survival in PDACs and we propose two possible explanations.  
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4.1.1! Sema3F as a potential important factor in PDACs 
 
Other interaction partners of NRP2 could block the binding of pro-tumorigenic molecules like VEGFs 
to NRP2 and therefore inhibit their oncogenic function including the NRP2/VEGFs axis. In fact, 
sema3F, a binding partner of NRP2 inhibits the functions of VEGF-A and VEGF-C in regard of 
endothelial cell migration and survival (Favier et al., 2006). Thus, the presence of the soluble sema3F 
in tumors could inhibit the pro-tumorigenic function of NRP2. The inhibition could lead to a reduction 
of vessel and tumor growth. In fact, the potential of sema3F treatment was already investigated and it 
was shown that it inhibits the tumor growth and progression in lung cancer cells (Potiron et al., 2007). 
Furthermore, Bielenberg received a grant for the investigation of the role of sema3F in pancreatic cancer 
and supervised the master thesis from Xiaoran Li which can be found in the internet. Li showed that 
sema3F is a potential treatment molecule for pancreatic cancer and functions through NRP2 (X. Li, 
2016).  
It would be interesting to stain the cohort for sema3F and check if the expression correlates with the 
survival rate, especially if a co-expression of sema3F and NRP2 is associated with a longer survival. 
Additionally, with the staining it would be possible to analyze if a low sema3F expressing and a high 
VEGF-C expression is associated with a poor prognosis. That could support to pro-tumorigenic function 
of VEGF-C and the anti-tumorigenic function of sema3F in PDAC and proof our hypothesis. 
Furthermore, the sema3F staining could show which cell types are mainly expressing sema3F, because 
it could be either secreted from tumor cells or from surrounding cells. Also, it would be interesting to 
analyze how much sema3F is needed to inhibit the binding of VEGFs to NRP2 therefore lead to a longer 
survival. In addition, an analysis should be performed to determine to what extent tumors cells must 
express NRP2 to have a positive effect on survival as well as if the amount of NRP2 has an impact on 
the prognosis. That could be done with a similar score as we used for the co-staining of NRP2 and 
VEGF-C but this time with NRP2 and sema3F. 
Also, it will be interesting to see the publication with the final data from Prof. Bielenbergs lab. In the 
master thesis, they performed a tumor model in mice, where they overexpressed sema3F and saw a 
reduction in tumor mass. The next step would be a treatment of an already established tumor with 
sema3F, which would mimic a realistic disease in humans. They used a virus for the over-expression of 
sema3F in their first approach. In the next step a treatment with sema3F or a blocking reagent should be 
performed to see, if they cause similar effects. Furthermore, an antibody treatment which is targeting 
the sema3 binding domain of NRP2 could be tested. Not only the tumor mass should be analyzed, but 
also the vascularization of the tumor. The blockage of the sema3F binding domain impairs the VEGF 
binding on NRP2 and therefore could lead to a reduced lymphangiogenesis and angiogenesis. 
Furthermore, the metastasis ability of the tumor cells could be inhibited and should therefore be 
considered.  
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All these anti-tumorigenic functions of sema3F, which were shown in cell culture and partly in mouse 
models, needs to be further elucidated. For example, other downstream effects of sema3F are possible 
in tumor cells or in surrounding tissue but could be NRP2 independent. Furthermore, the pathways 
triggered by NRP2 in different cells need to be analyzed in more detail. If the mentioned experiments 
support the hypothesis that sema3F treatment or blockage of the sema3-binding domain of NRP2 has an 
anti-tumorigenic effect, another promising target for drug development against tumor 
progression/metastasis would be found. 
 
4.1.2! NRP2b as a potential anti-tumorigenic splice variant 
 
We think, that the positive correlation between the survival and NRP2 expression in our experimental 
set up could also be caused by different splice variants of NRP2. NRP2a and NRP2b share the same 
extracellular structure but are significantly different in the intracellular part. Therefore, these two parts 
can be involved in very different downstream effects. In fact, it was shown that the PDZ domain 
expressed by NRP2a and NRP1 is essential for the complex formation between NRP1 and VEGFR-2. 
This domain seems to be of great importance and it is highly conserved across species suggesting an 
evolutionary impact (Prahst et al., 2008). If the PDZ domain of NRP1 was deleted, complex formation 
was impaired and hence the enhanced signal transduction related to NRP1 (Prahst et al., 2008). Due to 
the intracellular similarities between NRP1 and NRP2a, a related effect can be assumed for NRP2a. 
NRP2a and NRP2b share only 11 % of the intracellular amino acid sequence and NRP2b has no PDZ 
domain. One binding molecule of the PDZ domain is GIPC (Cai and R. R. Reed, 1999). Not much is 
known about the interaction and downstream functions of GIPC and NRP2a. Our lab showed that GIPC 
and downstream IGF-R are involved in tumor progression through the binding of the PDZ domain. An 
inhibition can lead to a reduction of proliferation in pancreatic cancer cells (Muders et al., 2009a; 2006). 
In conclusion, the expression of NRP2a with GIPC could favor proliferation and therefore lead to a pro-
tumorigenic profile in cancers and thus to an enhanced tumor growth.  
Furthermore, the hypothesis that the GIPC axis is involved in radio resistance was studied without a 
clear result, but the researcher suggested to further analyze the process (Singer et al., 2012). In summary, 
it could be that NRP2a has different tumorigenic functions than NRP2b. NRP2b cannot bind GIPC and 
is therefore not involved in downstream effects of GIPC. One paper focused on the differences of NRP2a 
and NRP2b in lung cancer cells. They found out that NRP2b expression inhibited the proliferation and 
primary tumor growth and therefore has anti-tumorigenic functions. But in the presence of TGF#, the 
anti-tumorigenic functions are revered and NRP2b concurs to be pro-tumorigenic. TGF# and NRP2b 
are involved in migration, invasion and metastasis.  Also, they analyzed NRP2a in their assays and found 
contrary effects compared to the overexpression of NRP2b (Gemmill et al., 2017).  
We conclude, that the splice variants can have different effects on the tumor progression. Whereas 
NRP2a is involved in the proliferation of tumor cells in the primary tumor, NRP2b affects the migration, 
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invasion and thereby the metastasis which is mostly the cause for death (Fidler and Balch, 1987; Sporn, 
1996). 
With this data in mind, we hypothesized, that in our experimental set-up we detected mostly NRP2a, 
which effects the primary tumor and not the ability to metastasize. A predominant expression of NRP2a 
would explain a better prognosis for PDAC patients.  
 
We hypothesize that the better prognosis associated with the higher expression of NRP2 is caused by 
NRP2a. This can be explained either because the expression of NRP2a and NRP2b is very different in 
PDACs, expressing mostly NRP2a in our case, or our antibody has a higher affinity to NRP2a. 
For our study, we used a monoclonal antibody according to Santa Cruz against the human amino acid 
sequence 560-858 of NRP2. Therefore, both NRP2a and NRP2b should be detected. First experiments 
with over expression of either NRP2a or NRP2b showed that the affinity of the antibody against NRP2b 
is not strong. A possible explanation for this could be the different posttranslational modifications of 
NRP2a and NRP2b. NRP2b, for example, is more easily sialylated (Rollenhagen et al., 2013). If 
sialylation or other posttranslational modifications have an impact on the binding affinity of antibodies 
is currently subject to further validation. 
To test if NRP2a and NRP2b are differently expressed in PDAC and have a different prognostic impact, 
it would be desirable to have antibodies that detect exclusively NRP2b or NRP2a and stain the TMA 
again. That study could show possible differences for NRP2a and NRP2b as prognostic marker. 
Currently no specific antibody against NRP2a or NRP2b is commercially available, but Gemmill et al. 
showed that a production of antibodies specifically detecting NRP2b is possible. Another approach 
would be to analyze the expression of NRP2 on RNA level. In that approach, a discrimination between 
NRP2a and NRP2b would be possible and even a detailed analyzation and subdivision of the different 
splice variants NRP2a (0), NRP2a (17), NRP2a (22), NRP2b (0), NRP2 (5) and S9 can be done.  
In fact, Cao at al. analyzed the RNA level and associated a high expression of NRP2 with a poor 
prognosis in PDAC patients. But they did not discriminate between NRP2a and NRP2b. Furthermore, 
they took only 88 patients from this cohort and only 20 % of the tumors showed NRP2 expression. A 
much higher percentage of positive tumors would be expected to express NRP2 due to the expression 
of NRP2 in many PDAC cell lines. Furthermore, the human protein atlas showed that most cells in the 
pancreas express NRP2. This is in line with our results, where nearly all tumor cells showed at least a 
low staining for NRP2. Cao at al. compared patients without NRP2 expression and the group with NRP2 
expression included only 17 patients. Because of the low number of patients and unexpected low number 
of positive tumors, further validation on RNA level is needed.  
It is important to point out that our study not only included more patients (207), but also analyzed the 
NRP2 expression on protein levels. Often, it is not possible to accurately conclude protein expression 
from RNA levels. There are many processes between transcription and translation which can affect the 
final protein level (Vogel and Marcotte, 2012). 
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4.1.3! VEGF-C as a prognostic marker in PDACs 
 
We further investigated the correlation between the survival of PDAC patients and the expression of 
VEGF-C. VEGF-C was the focus of many researchers as a potential prognostic marker. In fact, VEGF-C 
expression is associated with poor prognosis in many cancers including breast cancer (B. Liang and Y. 
Li, 2014), esophageal cancer (Tanaka et al., 2010) and gastric cancer (W. Cao et al., 2014). It was shown 
that VEGF-C is an important factor in lymphangiogenesis. Therefore, it is standing to reason that 
VEGF-C expression is also associated with metastasis. In fact, the poor prognosis and metastasis 
depending on VEGF-C expression was shown in esophageal cancer and breast cancer (B. Liang and Y. 
Li, 2014; Tanaka et al., 2010; Yang et al., 2015). It is important to note, that VEGF-C expression in 
cancer is not always associated with a poor prognosis. One study showed no correlation between 
VEGF-C expression and survival rate. That study was performed in breast cancer patients and therefore 
stands in contrast to Liang et al. (Yavuz et al., 2005). But the oncogenic ability of VEGF-C was further 
underlined by a study that showed that a knock-down of VEGF-C in an orthotopic nude mouse model 
with a human pancreatic cancer cell line inhibits tumor growth and lymphangiogenesis (Shi et al., 2013). 
Therefore, we postulated that VEGF-C could be a prognostic marker for PDACs, but no correlation 
between the VEGF-C expression and the survival was detected. First, it could be that VEGF-C has other 
functions in PDACs or has no major effect like in other cancer types such as breast cancer on the tumor 
progression. Also, VEGF-C functions through a receptor. Therefore, these receptors need to be available 
for binding for the function of VEGF-C. They could be blocked by other molecules, and therefore inhibit 
the function or are not expressed. Furthermore, a downstream inhibition could also occur. In addition, 
other molecules could bind to VEGF-C and therefore inhibit its function. To elucidate the possible 
tumorigenic role of VEGF-C and its potential as a marker in pancreatic cancer, more experiments need 
to be done. First, additional stainings of the TMA could be performed against binding partners of 
VEGF-C including VEGFR2, which is especially involved in lymphangiogenesis. Lymphangiogenesis 
increases metastasis which leads to a shorter survival (Perou et al., 2000). Another binding partner of 
VEGF-C is NRP2. Therefore, we analyzed the co-expression of these two proteins with the survival 
rate.  
 
4.1.4! Prognostic potential of co-expression of NRP2 and VEGF-C in PDACs 
 
NRP2 and VEGF-C are known binding and interaction partners and NRP2 can enhance the function of 
VEGF-C (Koch and Claesson-Welsh, 2012; Xu et al., 2010). Interestingly, it was shown by our 
cooperation partners, that the NRP2/VEGF-C axis is also important for the formation of autolysosomes 
and therefore for autophagy (Dutta et al., 2016). Autophagy is a self-digestive progress of damaged or 
misfolded proteins. Furthermore, it can provide cancer cells with additional nutrients for their rapid 
proliferation and thereby helps tumor cells to survive (Amaravadi et al., 2011; Chen and Karantza-
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Wadsworth, 2009; White and DiPaola, 2009). In addition, autophagy is involved in therapy resistance 
and targeting autophagy showed to have a beneficial effect for cancer therapy (Chen and Karantza-
Wadsworth, 2009; Cleveland, 2008). Therefore, we checked if NRP2 expression in our cohort has a 
correlation with the survival rate after treatment but found no different. 
But a combined analysis of NRP2 and VEGF-C could be highly interesting due to their known functions 
in cancers.  
But no significant difference was found between a high expression of NRP2 and VEGF-C in a tumor 
compared with a low expression. As discussed above, that could be because the binding side of NRP2 
for VEGF-C is blocked. Therefore, the oncogenic function of VEGF-C through NRP2 is not triggered. 
One competitor for VEGF-C binding to NRP2 is sema3F. As discussed above, sema3F can inhibit the 
progression of cancer and could at least partly block the function of VEGF-C through NRP2 (Koch and 
Claesson-Welsh, 2012; Xu et al., 2010).  
 
In summary, high NRP2 expression correlates in our PDAC cohort with a longer survival. That is 
contrary to results from other studies in other cancer types but can be explained by either a cancer 
specific effect, by specific isoform expression of NRP2 or by interaction partners of NRP2, which can 
trigger different effects and are competitors for binding. Furthermore, that could explain that a 
co-expression of VEGF-C and NRP2 has no correlation on the survival rate. High VEGF-C expression 
alone showed no correlation on the survival rate unlike in other cancer types. That could be either a 
cancer specific effect, or again be explained through the competition for binding at NRP2. NRP2 can 
enhance the VEGF-C signal, but without the binding the downstream effects of VEGF-C could be 
reduced (Koch and Claesson-Welsh, 2012; Xu et al., 2010). 
Further analysis in regard of the splice variants of NRP2 and other binding partners including sema3F 
would elucidate the roles of NRP2 and VEGF-C and their potential as biomarker in PDACs. The 
NRP2/sema3 axis especially holds great potential for further investigations in context of the tumor 
pathology, tumor progression and in the end as a treatment target. They came into focus as potential 
drug targets in various cancers, but hold different effects depending on the sema3 family member and 
the cancer type (Gaur et al., 2009; Nasarre et al., 2014). 
 
 
4.2! Effects of NRP2 deficiency on macrophages and the role of NRP2 in 
immune cells during tumor progression in mice 
 
We found high NRP2 expression in macrophages around the PDAC in our cohort, but not much is 
known about the function and effect of the expression of NRP2 in TAMs. To investigate the role of 
NRP2 in macrophages we used mouse models with cre-LoxP system.  
 
Discussion
 
61 
4.2.1! Effects of NRP2 depletion on macrophages 
 
For our statistic with qPCR samples we first used the F-Test to analyze the variability of the samples. If 
the F-Test is positive, the samples have a high variability. That can interfere with the T-Test and results 
in smaller p-values. To have reliable p-values we performed only a T-Test on samples where the p values 
of the F-Test were >0,05 and therefore negative. The Mann-Whitney T-Test is independent of the 
variants and was used when the F-Test was positive.  
 
First, we analyzed the expression of NRP2 in murine macrophages. During the differentiation of 
monocytes towards macrophages, NRP2 is expressed. We showed that M1-macrophages express thrice 
as much NRP2a and NRP2b compared to undifferentiated macrophages. The T-Test for both splice 
variants had a p value of < 0,01 and is therefore highly significant. In the case of NRP2b the F-Test was 
positive. Because of the high variability of the samples we performed an additional analysis with the 
variant independent Mann-Whitney-Test which showed a p value of <0,001.  
 
Ji et al. claimed that a treatment with LPS significantly decreases the NRP2 expression in macrophages 
and thus their data seem to stand in contrast to our results. It can be assumed that the disparity is caused 
by the very different experimental procedure. We cultured the bone marrow monocytes for 7 days 
followed by a stimulation with LPS for four hours. They used freshly isolated human monocytes and 
cultured them for one day with or without LPS (Ji et al., 2009). To get fully differentiated macrophages 
from monocytes, a culture of 7-8 days is necessary (Cassol et al., 2009). Therefore, it is questionable if 
monocytes after one day of culture are sufficiently differentiated, especially towards a M1 profile and 
thus a comparison cannot be made. We analyzed marker genes for M1-macrophages to check the 
experimental set-up and the genes were upregulated. Conclusively, we showed that both NRP2a and 
NRP2b, are upregulated during the differentiation towards M1-macrophages.  
Next, we investigated if a knock-out of NRP2 in macrophages impaired the polarization of 
M1-macrophages. BMDM from LysM:cre-NRP2LoxP/LoxP mice showed a knock-out efficiency of more 
than 95 % for both splice variants before and after polarization towards M1-macrophages. We analyzed 
the M1-profile of the NRP2 ko cells and found no regulation in marker genes. Thus, we concluded that 
NRP2 is probably not essential for the differentiation towards M1-profile but possibly is involved in 
important processes in M1-macrophages, otherwise an expression of NRP2 during the differentiation 
and a significant increase during the polarization would be unnecessary.  
Besides, we analyzed M2-macrophages. Polarization triggered with IL-4 leads to an increase (1,5 x) of 
NRP2a and NRP2b but without a significance. Next, we analyzed if a NRP2 knock-out in 
M2-macrophages had an influence on marker genes for M2-macrophages and we found no regulation. 
We conclude that NRP2 is not essential for the upregulation of genes for the M2 profile.  
Discussion
 
62 
In summary, NRP2a and NRP2b are expressed in macrophages and both isoforms are similarly 
upregulated during the polarization towards M1- or M2-macrophages. Furthermore, a knock-out of 
NRP2 affects both splice variants and has no impact on certain marker genes of M1- or 
M2-macrophages. Thus, it is likely that NRP2 is not important for the respective polarization of M1- or 
M2-profile of macrophages. The data showed, that both subpopulations of macrophages can evolve 
without NRP2.  
 
During tumor progression, a sufficient supply of nutrients and oxygen is essential to enable a rapid 
growth of cancer. Tumor cells distant from vessels lack the crucial supplies and face cell death. One 
form of cell death is necrosis, which is caused by external factors including lack of nutrients. The 
“angiogenic switch” is the transition from a hyperplasia to an outgrowing tumor with a vascularization, 
and therefore an essential process for growing malignant cancer (Baeriswyl and Christofori, 2009; 
Riabov et al., 2014). It is caused through angiogenic factors, which are mainly produced from recruited 
macrophages (Lin and Pollard, 2007). Macrophages are an important cell type in tumor progression and 
have a variety of functions depending on their expression profile. During cancer promoting and 
initiation, macrophages showed an “activated” phenotype like M1-macrophages (S. Gordon, 2003). This 
changes with the progression of the cancer. Pro-inflammatory proteins including iNOS and TNF-& were 
reduced and macrophages switch their profile towards M2 (Pollard, 2009; Saccani et al., 2006) and 
support the vascularization. A major driver for vessel formation and the most important for cancer 
vascularization is VEGF-A (Sitohy et al., 2012). Therefore, we further analyzed the expression of 
VEGF-A in macrophages. Unsurprisingly, VEGF-A expression in M1 macrophages is reduced, whereas 
M' and IL-4 stimulated M2-macrophages had unchanged levels. A knock-out of NRP2 did not affect 
the expression in either M' and M2-macrophages.  
Furthermore, the importance of macrophages for tumors is further underlined by the fact that in most 
cancers a high infiltration of macrophages is associated with a poor prognosis (Pollard, 2004). 
 
4.2.2! Analysis of NRP2 deficient macrophages on LLC growth 
 
Next, we investigated the tumor growth in a mouse model with NRP2 deficient macrophages. We used 
the LysM:cre mouse line where the cre-recombinase is expressed under the LysM promoter and crossed 
it with the NRP2LoxP/LoxP mice. The cre-recombinase cuts the LoxP sides in these cells and causes a 
depletion of the NRP2 expression. A depletion of the target gene occurs in 83 – 98 % of the mature 
macrophages. Also, nearly all granulocytes and 16 % of DCs are targeted (Clausen et al., 1999). Because 
only two cell types, mature macrophages and granulocytes, are targeted in the LysM:cre mouse, it is a 
strong tool for the analysis of macrophages in vivo. The knock-out in DCs was only detected in 16 % of 
the splenic DC population and is therefore negligible for our model. 
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We focused on the role of macrophages during tumor progression. One good model is the subcutaneous 
injection of LLC cells because the dominant leukocyte population in these tumors are macrophages with 
ca. 63 % (C. Lee et al., 2017). We found no difference in tumor size between wt and 
LysM:cre-NRP2LoxP/LoxP mice in two separate experiments.  
A different conditional knock-out mouse model might be able to show an effect on the tumor growth. 
As described above the knock-out of NRP2 in LysM:cre mice takes place in activated macrophages. 
Thus, we next used a model with a knock-out of NRP2 before the monocytes differentiated towards 
macrophages. Herewith we can analyze if the deficiency of NRP2 in macrophage precursors has an 
impact on the function of macrophages during tumor growth. It is possible that a knock-out could 
preferentially drive macrophages towards a specific profile like M1 or M2 similar as it was described in 
NRP1 deficient macrophages (Nissen et al., 2013; Nissen and Tsirka, 2016). The LysM:cre mouse model 
is not able to show these effects. In addition, it is known that NRP2 is expressed and involved in 
migration of many immune cells (Curreli et al., 2007; Mendes-da-Cruz et al., 2014; Stepanova et al., 
2007).  
To investigate if an early knock-out of NRP2 affects the tumor growth in immune cells, we used a mouse 
line where the cre-recombinase is under the Vav promoter. Vav is active in hematopoietic stem cells 
and therefore the NRP2 knock-out occurs at the beginning of the maturation of immune cells. It is 
important to note that in this model the whole hematopoietic system is targeted (Stadtfeld and Graf, 
2005). In addition to macrophages, other immune cells play important roles in tumor progression 
including DCs and T cells. They are the predominant immune cells next to macrophages in tumors 
(Shiao et al., 2011). Infiltrating T cells can either have a positive effect on the survival rate or contrary 
can have an immune-suppressive profile (Curiel et al., 2004; Tran Janco et al., 2015; L. Zhang et al., 
2003). Analogically, DCs can have either a pro- or anti-tumorigenic character. They can activate 
immune cells, especially T cells, and provoke an inflammatory milieu to fight tumor cells. Alternatively, 
they can also function as immune suppressor and protect the tumor cells and support its progression 
(Krempski et al., 2011; Ma et al., 2013; Scarlett et al., 2012; Tran Janco et al., 2015). Both T cells and 
DCs express NRP2, and in both cell types NRP2 is involved in migration (Curreli et al., 2007; Mendes-
da-Cruz et al., 2014; Stepanova et al., 2007). It is not known if NRP2 on these cells influences the tumor 
growth or progression. With the Vav:cre mouse model we can analyze the effect of an early knock-out 
of NRP2 in the whole immune system during the progression of the LLC tumor.  
 
4.2.3! Influence of NRP2 deficiency in hematopoietic stem cells on bones and blood cells 
 
Previously, Verlinden et al. showed that a complete knock-out of NRP2 leads to trabecular bone loss. 
Furthermore, they found more osteoclasts and a reduction of osteoblasts (Verlinden et al., 2013). 
Additionally, they showed that hematopoietic precursor cells do not express NRP2, but during a 
cultivation, NRP2 is upregulated in hematopoietic precursors as well as during the differentiation of 
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osteoblasts. Osteoclasts originate from hematopoietic precursors like macrophages and are therefore 
also affected by the Vav:cre mediated knock-out, unlike osteoblasts which originated from stroma cells 
(Bar-Shavit, 2007). Furthermore, T cells and NK cells can enhance osteoclast formation (Wythe et al., 
2014). Thus, we analyzed the bones of Vav:cre-NRP2LoxP/LoxP mice and found no difference. We 
conclude that a knock-out of NRP2 in hematopoietic cells, including osteoclasts or T cells, has no effect 
on bone formation and thus the effect described by Verlinden et al. is most likely caused by other NRP2 
expressing cells. There needs to be more work done to elucidate the role of NRP2 in bone development 
and homeostasis with other specific mouse models, specially focusing on osteoblasts like the Osx;cre 
mice. For our work, it was important to rule out any effect of a NRP2 knock-out on bone mass because 
that could influence the developing and later circulating immune cells from the bone including 
macrophages. Furthermore, we checked the immune cells in the blood of Vav:cre-NRP2LoxP/LoxP mice to 
check for any chances in the composition of blood triggered by the conditional knock-out. No 
differences were found in regard of cells and other blood factors. In conclusion, NRP2 knock-out in the 
hematopoietic system has no effect on the bone mass or on the composition of the blood.  
 
4.2.4! Effects of NRP2 deficient immune cells on tumor pathology 
 
Next, we performed the LLC tumor model with the Vav:cre-NRP2 mice to analyze the effect of an early 
knock-out of NRP2 in the immune system. Again, no difference in tumor size was detected. 
 
To prove that NRP2 is expressed in tumor infiltrating immune cells of wt mice, an antibody staining 
would be the method of choice. Unfortunately, in the last couple of years no reliable NRP2 antibody for 
mice was available for our set-up. Therefore, we sorted cells out of tumor tissue and performed a qPCR. 
Our preliminary data showed that macrophages, T cells and neutrophils express NRP2. Whereas the 
expression of NRP2 in T cells and macrophages in the tumor tissue were expected, neutrophils are 
another immune cell type which showed NRP2 expression on mRNA level. Furthermore, we checked 
for the NRP2 expression in macrophages from Vav:cre-NRP2LoxP/LoxP mice and found a ca 90 % 
reduction of NRP2 on mRNA level. Obviously, the experiment needs to be repeated to prove this 
preliminary data. It would be highly interesting to prove that neutrophils express NRP2. Such a broad 
expression of NRP2 in immune cells would further underline the hypnosis that NRP2 has important 
functions in the immune system. In the last year, more antibodies came on the market from different 
companies against human and mouse NRP2 and therefore a verification of our proposition on protein 
level should now be possible in regard of the expression of NRP2. 
 
In our experimental set-up, we found no regulation in tumor size in two mouse lines with conditional 
knock-out of NRP2 in immune cells. It is possible that NRP2 in immune cells has no important function 
regarding the tumor progression and conclusively on the size of the cancer. The questions remain, why 
Discussion
 
65 
is NRP2 strongly expressed in TAMs and other immune cells? We think that a change of the experiment 
set-up could yield better results. We had to stop the experiment early because after ca. 14 days in some 
mice the tumor broke open the skin and caused bloody wounds. Small differences can have bigger effects 
on slow growing cancers and some effects might be measurable only in later tumor stages. Therefore, a 
moderate and slow growing tumor or a spontaneous developing tumor might be better to study the effect 
of a knock-out of NRP2 in immune cells.  
 
4.2.5! The role of NRP2 on the vascularization in LLC tumors 
 
Next, we analyzed the tumors in more detail. One important feature for cancer cells is their ability to 
form metastases. LLC cells are especially known to metastasize into the lung (Vandereyken et al., 2017; 
Y. Wang et al., 2017). TAMs are critical for not only tumor progression but also for tumor angiogenesis 
and metastasis. This can be independent of the primary tumor growth (Lin et al., 2006; 2001). VEGF-A, 
VEGF-C and VEGF-D are expressed from TMAs and are important factors for angiogenesis and 
lymphangiogenesis. These two processes are closely associated with metastasis and link TAMs to the 
process of metastasis through the expression of different VEGFs (Cursiefen et al., 2004; Iwata et al., 
2007; Jeon et al., 2008; Lin et al., 2006; 2001; 2007; Riabov et al., 2014). VEGFs are interaction partners 
of NRP2. We next analyzed the effect of the conditional knock-out of NRP2 and the expression of CD31 
in the tumor tissue. CD31 is a marker for endothelial cells that detects both angiogenic and 
lymphangiogenic vessels (Baluk and McDonald, 2008). First, we used paraffin embedded LLC tumor 
slides and scored blinded sections depending on their staining. We found a significant reduction of CD31 
staining in both LysM:cre-NRP2LoxP/LoxP and Vav:cre-NRP2LoxP/LoxP compared to the wt. The reduction 
was stronger in Vav:cre-NRP2LoxP/LoxP mice which was anticipated. The knock-out of NRP2 in 
macrophages in Vav:cre mice occurs earlier, is more efficient, and independent of the maturation stage 
compared to the LysM:cre mice, where 83 – 98 % of the mature macrophages are affected. It is important 
to note that all immune cells in the Vav:cre mice are targeted, and therefore could have an impact on the 
vessels like T cells (Benencia et al., 2012). It is very likely that the main cell type for the effect are 
macrophages. They are the most abundant immune cell type in the LLC tumor, are known for their role 
in angiogenesis and lymphangiogenesis, and are also targeted in the LysM:cre mice. The only other cell 
type affected in both mouse lines, are granulocytes. In fact, the most abundant granulocyte, the 
neutrophils, can infiltrate tumors and are associated with a poor prognosis (Carus et al., 2013; Walsh et 
al., 2005; Yutong et al., 2015). Furthermore, they are an important source for angiogenic factors, and 
thus are involved in angiogenesis like TAMs (Gaudry et al., 1997; W. Liang and Ferrara, 2016). It is 
important to note the NRP2 expression on neutrophils or granulocytes is insufficiently described up until 
this point (Schellenburg et al., 2017). The sorted neutrophils out of the LLC tumor showed NRP2 
expression on RNA level but the results are currently questionable because it was only performed once. 
Therefore, we would strongly encourage a further analysis of granulocytes in tumors because NRP2 
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might be expressed and has an impact on angiogenesis. Due to the insufficient data regarding 
granulocytes in our model and the smaller cell number in the LLC tumor, possible functions are highly 
speculative. 
 
To further support our data, we performed a fluorescence staining against CD31 on frozen tissue. The 
analysis was performed using ImageJ, and therefore subjective failures in the experimental set-up were 
ruled out. Again, we saw a strong reduction of CD31 staining in LysM:cre tumors. With a p value of 
0,0571, it was close to significant. Unfortunately, we had only a few samples which is likely the reason 
for the p value > 0,05.  
Furthermore, fluorescence staining of Vav:cre-NRP2LoxP/LoxP would be good to further support the results 
and show the significance of the data.  
We tried a fluorescence staining with both CD31 antibodies on paraffin embedded slides, but up to now 
the staining was not evaluable due to difficulties in the method or impractical antibody for that set-up. 
Next, we checked for M2-macrophages in the tumors with a CD206 staining. CD206 is a common 
M2-macrophage marker. A difference in TAMs could be a reason for the reduction of the CD31 staining. 
We counted the percentage of CD206 positive cells and analyzed the fluorescence intensity in regard of 
the tumor area. Both approaches showed no difference. An additional staining to detect all macrophages 
(with e. g. F4/80) and a specific staining for M1-macrophages (with e. g. CD86), would show if a knock-
out of NRP2 causes a distribution of pro- and anti-inflammatory macrophages. M1-macrophages could 
inhibit the pro-tumorigenic profile of TAMs. In fact, it was shown that a shift towards M1-macrophages 
can lead to a reduction of LLC tumors (C. Lee et al., 2017). Furthermore, it was shown that NRP1 is 
involved in the polarization of macrophages (Nissen et al., 2013; Nissen and Tsirka, 2016). A similar 
effect could be possible for NRP2. The interaction of cells with macrophages, in addition to cytokine 
expression and secretion, are important for the polarization of macrophages. A knock-out of NRP2 could 
impair the contact with macrophages or lead to a reduction of pro-angiogenic factors or an impaired 
TAM profile.  
Additionally, the location of infiltrating macrophages is important for the clinical outcome. TAMs 
infiltrating tumor nest are associated with a better prognosis (Shih et al., 2006). Furthermore, NRP1 in 
murine TAMs is involved in the migration of the cells into hypoxic areas and effects the angiogenesis 
(Casazza et al., 2013). A closer analysis of the location of NRP2 deficient TAMs could give a better 
insight as to how and why they influence the vascularization. Perhaps the migration of NRP2 deficient 
TAMs towards or into hypoxic areas is impaired because NRP2 interaction partners like plexins and 
sema3s are involved in the process (Casazza et al., 2013). This could lead to different release of 
angiogenic factors by TAMs. 
Furthermore, it would be interesting to analyze VEGF-A and VEGF-C in the tumor to see if a reduction 
of these two important factors is responsible for the impaired vascularization. Next, a closer analysis 
including VEGF-A and VEGF-C expression in TAMs would be crucial to see if NRP2 is involved in 
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the regulation of the expression of these factors in macrophages, or if a possible deregulation of 
angiogenic factors in the tumor is caused by a different cell type. 
It is reasonable to assume that a reduction of vessels leads to more necrotic cell death and therefore 
larger necrotic areas in the tumor due to an insufficient supply of nutrients. Necrotic areas can be 
identified by abnormal cell shape. The membrane becomes permeable, organelles dilate, and the nucleus 
disintegrates (Ziegler and Groscurth, 2004). A pathologist marked the necrotic areas of the LLC tumors 
blinded, and we calculated the percentage of affected area. In total, the necrotic areas in the conditional 
knock-out models were increased, but the standard deviation was very high. Therefore, no reasonable 
conclusions can be drawn so far with these results. More slides and tumor tissues need to be analyzed. 
A cytochrome-c staining and/or a TUNEL staining would be good methods to come to conclusive results 
about the role of NRP2 in immune cells on the supply of nutrients for tumor cells.  
 
Conclusively, more work needs to be done to elucidate the role of NRP2 in tumor infiltrating immune 
cells on the vessel formation and necrotic areas.  
 
Next, we checked the lungs for metastasis, but did not find any in the wt nor in both conditional knock-
out mice. This is unusual because LLC tumors are known to metastasize. But it is likely that the short 
growing time of the tumor was not sufficient for the development of metastases. We tried to increase 
the growing phase of the tumors by injecting less cells, but either the tumors were only marginally 
delayed, or did not develop depending on the numbers of cells we used. Furthermore, others injected the 
LLC cells in the axillae or directly in the tail vein of mice to study metastasis. The location of the tumor 
could play a role in regard to their velocity to metastasize. Additionally, most researchers let the tumors 
grow for more than 20 days (C. Lee et al., 2017; Vandereyken et al., 2017; Y. Wang et al., 2017; Wu et 
al., 2017; Yamauchi et al., 2013; X. Zhang et al., 2016).  
In conclusion, NRP2 in immune cells influences the tumor pathology in regard to vessel formation. It is 
likely that these results are transferable to other tumor models, which can also further elucidate the 
potential effect of a NRP2 knock-out in macrophages on tumor growth and metastasis. In fact, with our 
cooperation partners, we established a different experimental set-up and found promising results in a 
first experiment. A tamoxifen induced knock-out in TAMs led to a slower tumor progression. These 
results were presented at the “Deutsche Gesellschaft für Pathologie 2017”. Furthermore, our cooperation 
partners and we could show that NRP2 is involved in endocytosis in cancer cells (Dutta et al., 2016). 
Endocytosis is an important process in monocytes and macrophages to clear pathogens and cells and is 
important for cancer progression (S. R. Gordon et al., 2017). A knock-out of NRP2 in macrophages 
could impair the ability to endocytose tumor cells/dead cells in a cancer and by that affect the immune 
response against an increased number of dead tumor cells. A closer analysis of the endocytosis of 
isolated TAMs without NRP2 would be highly interesting and could give further indications about the 
role of NRP2 in immune cells during tumor progression. 
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In summary, NRP2 has the potential to be important in many processes during tumor progression 
including endocytosis, migration, and vessel formation. More work needs done to prove and elucidate 
the function of NRP2. Furthermore, an analysis of the role of NRP2 in TAMs for metastasis could be 
highly interesting.  
Our data in context with the literature strongly suggests important functions of NRP2 in immune cells. 
Therefore, we further investigated the role of NRP2 during an inflammation with a mild allergic model 
of the lung. 
 
 
4.3! The role of NRP2 in during an inflammatory response 
 
In the innate and adaptive immune response, many progresses and interactions between immune cells 
are necessary for an appropriate immune reaction. Interference of these complex progresses can have 
crucial downstream outcomes on the immune response. The system could over react and causes damage 
to endogenous tissue, lead to a chronic inflammation which can results in cancer or an autoimmune 
disease. In contrast, an impaired inflammation could interfere with the fighting of exogenous particles 
and the healing process.  
The adaptive immune response is highly specific against pathogens. APCs activate B and T cells and 
trigger the antibody response and cell-mediated immune response through certain antigens. High 
sensibility against specific antigens can cause an unnecessary inflammatory response which can results 
in diseases including allergies.  
Neuropilins were found to be expressed in APCs including macrophages and DCs. DCs are the most 
important APC. Both neuropilins are expressed and involved in the migration of DCs (Rey-Gallardo et 
al., 2010; 2011; Takamatsu et al., 2010). Furthermore, it was shown that NRP1 is important for the 
formation of the interspace between APCs and T cells called immunological synapse (Tordjman et al., 
2002). So far, it was not shown if NRP2 is likewise located in the immunological synapse but that NRP2 
is also important for the activation of T cells. A blockage of NRP2 leads to an activation and proliferation 
of T cells (Curreli et al., 2007). Furthermore, it was shown that NRP2 is expressed on both CD4+ and 
CD8+ T cells and is involved in the migration of T cell precursors called thymocytes (Mendes-da-Cruz 
et al., 2014). In addition, the importance of NRP2 in CD4 T cells was pointed out during the AACR 
meeting by showing that NRP2 deficient T helper cells were hyper-proliferative and express markedly 
increased pro-inflammatory cytokines including IL-2, IFN" and IL-17 (H. Nakayama et al., 2015). These 
data suggest that NRP2 is an important factor for the adaptive immune response and a blockage/knock-
out of NRP2 in immune cells could result in a proliferation of T cells. Furthermore, the NRP2 deficient 
CD4+ T cells could further enhance the inflammation due to an upregulation of pro-inflammatory 
cytokines. The complex interaction of immune cells triggered by an antigen can be best analyzed in vivo 
with an entire immune system. Therefore, we used a mild allergic model of the lung to investigate the 
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role of NRP2 during an inflammation. The reaction in NRP2 deficient immune cells triggered with 
repeated stimulation with ovalbumin could either lead to a stronger immune reaction due to an increase 
of T cells or a milder inflammation because the migration of important cells is impaired according to 
the literature. The Vav:cre-NRP2LoxP/LoxP mouse was the model of choice due to the conditional 
knock-out in immune cells, without causing any detectable difference in bones or blood system. We 
counted all leucocytes followed by an analysis of the different immune cell populations in the BALF. 
The NRP2 knock-out in immune cells had no effect on the macrophage, neutrophil and B cell 
populations. The signals from the flow cytometry for the DCs in the BALF were very few and therefore 
no clear population was visible. For that reason, we excluded it from our analysis. A higher number of 
applied cells would give more signals and therefore would create more reliable data. Nevertheless, a 
difference between the wt and Vav:cre-NRP2LoxP/LoxP mice was not detected (data not shown).  
The most abundant immune cell type in the BALF were T cells. Especially CD4+ cells are important 
during allergic responses in the lung (Kay, 2006; Toussaint et al., 2013). We found a significant 
reduction of T cells in the BALF in the conditional ko mice. A further separation showed that both CD8+ 
and CD4+ T cells are reduced. The activation of T cells during an allergic response is orchestrated by 
macrophages and DCs. Especially Th2 T cells and their corresponding cytokines are important during 
an allergic inflammation (Toussaint et al., 2013). 
Macrophages are the most abundant immune cell type in the healthy lung and it was shown previously 
that they express NRP2 (Aung et al., 2016; Byers and Holtzman, 2011). Macrophages have inhibitory 
functions and influence the immune response triggered by DCs (Bedoret et al., 2009; Holt et al., 1993; 
Toussaint et al., 2013). During the adaptive immune response in the lung, DCs would migrate towards 
the bronchial lymph node (BLN) to present antigens like ovalbumin to T cells (Toussaint et al., 2013). 
The knock-out of NRP2 could have an impact on these processes and therefore could lead to a reduction 
of T cells. The inhibition of DCs from macrophages could be stronger in the conditional knock-out 
through a deregulation of cytokines like IL-10 which restrains DC functions (Toussaint et al., 2013). 
More likely is that the migration of NRP2 deficient DCs is impaired. Previously it was shown that NRP2 
enhances the migration of DCs. Especially the posttranslational modification polysialylation on NRP2 
is essential for that process (Rey-Gallardo et al., 2011; 2010). To elucidate if DCs are responsible for 
the regulation, the BLN should be analyzed for migrated DCs in the next experiment. A difference in 
DCs in the BLN could explain a reduced activation of T cells. Furthermore, an additional experiment 
with a mouse model targeting specifically DCs like the CD11c:cre mouse would pin point the effect on 
the DCs.  
Also, it is possible that the knock-out of NRP2 in T cells can lead to an impaired activation, cytokine 
production and therefore to a reduced proliferation. We first expect an increased number of T cells 
because during the AACR conference Nakayama et al. presented results showing that NRP2 deficient 
CD4+ cells are hyper-proliferative. Furthermore, they produced higher amounts of IL-2, IFN" and IL-17 
(H. Nakayama et al., 2015). These cytokines are involved in the proliferation of T cells and an 
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upregulation could therefore explain or enhance the increased proliferation (Crawley et al., 1997; J. M. 
Reed et al., 2008).  
Furthermore, the regulation of eosinophils during the inflammation is highly interesting. Eosinophils 
are important cells during allergic reaction and are indicators for the severity of the  inflammation by 
causing hyper-responsiveness and mucus accumulation (Kay, 2005; Korsgren et al., 1997; Nakajima 
and Takatsu, 2007). We analyzed the mucus with a Pas staining. Due to the short and mild allergic 
model, not many cells were positive. An increased inflammation could cause an uptake of Pas positive 
cells. Because in the conditional knock-out we found fewer inflammatory cells we would expect a 
reduction of the Pas staining but most likely due to the brief ovalbumin challenge, a potential difference 
between the wt and the Vav:cre-NRP2LoxP/LoxP mice was not pronounced. 
It is important to note, that eosinophils can also function as APC but to a much lesser extent than DCs. 
It was shown in a similar allergic model that ovalbumin challenged eosinophils can active T cells, 
especially Th2 T cells and therefore cause a production of Th2 cytokines (MacKenzie et al., 2001; Pozo 
et al., 1992). So far it is not known if eosinophils express NRP2 or if NRP2 is important during the 
activation or migration of eosinophils. But due to the fact, that in our mouse model the numbers of 
eosinophils are significantly reduced, NRP2 is likely an important player for these cells.  
Otherwise, an impaired production of cytokines could affect the numbers of eosinophils. IL-5 is a very 
important factor for eosinophils and their progenitors. It is involved in proliferation, migration, survival, 
maturation, differentiation, chemotactic activity and adhesion (Dent et al., 1990; N. A. Lee et al., 1997; 
Nakajima and Takatsu, 2007; Rothenberg and Hogan, 2006; Tominaga et al., 1991; Yamaguchi et al., 
1988). Th2 cells are a main producer of IL-5. Therefore, a reduction during the inflammation of T cells, 
mainly consisting of Th2 cells, could also lead to a reduction of eosinophils.  
Furthermore, Nakayama et al. claimed that the NRP2 deficient CD4+ T cells are not only hyper-
proliferative but also produce more IL-17. IL-17 is highly expressed in Th17 T cells. That could indicate, 
that a knock-out of NRP2 leads to an increased differentiation towards Th17 T cells. An impaired 
differentiation of T cells could further enhance the reduction of eosinophils through a reduced IL-5 
expression.  
To find and support explanations for the decrease of T cells and eosinophils in our model, we started to 
further analyze T cells. First, we analyzed the NRP2 expression in different T cells. Surprisingly, the 
NRP2 expression is very different between the subpopulations of T cells. CD8+ T cells express 10 times 
as much NRP2 on mRNA level compared to naïve CD4+ T cells. It is known, that both CD4+ and CD8+ 
T cells express NRP2 on protein level (Mendes-da-Cruz et al., 2014). The researchers investigated the 
percentage of NRP2-containing cells by flow cytometry in the different populations but did not comment 
if one cell type expresses more NRP2 than the other. Furthermore, they found out, that during the 
maturation less CD4+ T cells express NRP2. Therefore, we analyzed the NRP2 level in the CD4+ 
subpopulations. In fact, the NRP2 level are very different between the populations. Th1 is not expressing 
NRP2 at all and Treg cells only to a minor extent but Th2 and especially Th17 cells express NRP2. It 
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seems, that NRP2 is not important for Th1 cells but very likely in Th2 and Th17 cells. That would further 
support the hypothesis, that NRP2 might have important functions that are cell type-specific.  
We started to analyze the effect of a NRP2 knock-out in different population of T cells. NRP2 deficient 
CD8+ cells show a small reduction of the pro-inflammatory and proliferative cytokines IL-2 and INF". 
It would be interesting, if some significant regulations of CD8+ cytokines can be detected on protein 
level and later during an inflammation in vivo.  
Next, we focused on the T helper cells Th1, Th2 and Th17. As expected, we found no regulation on 
mRNA level in Th1 cytokines which underlines that NRP2 might not be important for Th1 cells. 
Interestingly, no regulation of different Th17 cytokines were detected on mRNA level. Except IL-13 
might be regulated and should be further analyzed. In our approach, it was reduced by ca. 46 % but not 
significantly. Th17 cells expressed the highest amount of NRP2 on RNA level, but up to now we did 
not find any deregulated genes. Obviously, we just analyzed a fraction of interesting genes and did not 
perform any functional assays. But in contrast to the data from Nakayama et al., we found no increase 
of IL-17 expression, which would mainly be expressed by Th17 cells (H. Nakayama et al., 2015).  
We were especially interested in Th2 cells due to their dominant role during the allergic inflammation 
model and identified some deregulated cytokines. Significantly upregulated were the cytokines IL-13 
and IL-5. Both are known for their pro-inflammatory functions and are especially important during 
allergic reaction in the lung like asthma. IL-13 is an important mediator during allergic lung disease and 
influences many immune cells including DCs and macrophages. IL-13 shares similar functions as IL-4 
but mostly with a milder effect. IL-4 is involved in many immune processes and can enhance the 
capacity of DCs to stimulate T cells. Contrary to IL-13, IL-4 was reduced in NRP2 deficient Th2 cell 
(Antoniu, 2010; Becerra-Díaz et al., 2017; Kouro and Takatsu, 2009; N. A. Lee et al., 1997; T. 
Nakayama et al., 2017; Thavagnanam et al., 2011; Webb et al., 2007).  
IL-5 is essential for eosinophils and was significantly increased in Th2 cells. This observation was 
surprising because in the mouse model the number of eosinophils were highly reduced. But it can be 
that the amount of IL-5 in the wt mice is still higher because of the higher number of T cells. 
Additionally, the anti-inflammatory cytokine IL-10 is upregulated in Th2 cells and could therefore 
suppress the immune response. The deregulation of genes in cell culture is highly interesting and 
showed, that NRP2 ko has an effect on the Th2 cells, but the cell culture data alone cannot explain the 
impaired inflammation. A speculation due to the up-/ down-regulation of certain genes is tempting but 
to elucidate the function of NRP2 more experiments need to be performed.  
Furthermore, a NRP2 ko in T cells might impair the maturation towards certain T cell populations and 
favors other cell types, for example Th17 T cells or Th1 T cells. The upregulation of IL-17 in the cell 
culture experiment of Nakayama could be explained by an increase of Th17 T cells and therefore could 
underline the hypothesis.  
The deregulation of genes in Th2 cells are promising results and further supports the hypothesis of an 
important role of NRP2. An asthma model might be the best model to understand more about the role 
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of NRP2. During a longer allergic reaction more immune cells could migrate into the lung and interact 
and activate additional cells. That could lead to a stronger effect on the immune cell populations. The 
BALF could again be isolated and analyzed by flow cytometry to see any change in the different 
populations with a special interest in the T helper cell subpopulations. Furthermore, a sorting could be 
performed of the T cells followed by a qPCR to check if the genes are also regulated in vivo during an 
inflammation in addition to ELISA to analyze the protein level of certain cytokines in the BALF. That 
experiment could further elucidate the impact of NRP2 on the immune response and could help to 
support our data and proof our hypothesis. 
 
 
4.4! Conclusion 
 
We showed that NRP2 can be used as a prognostic marker in PDACs and is associated with a longer 
cancer specific survival. In other cancers, NRP2 is mostly associated with a poor prognosis. We 
speculated that the results were either specific for PDACs, isoform specific or due to a competition of 
interacting partners of NRP2.  
Additionally, we found high expression of NRP2 in TAMs and investigated the role of NRP2 in immune 
cells during cancer progression. We showed that a knock-out of NRP2 in immune cells led to a reduction 
of vascularization in the tumors. Different tumor models could further elucidate the role of NRP2 on the 
vascularization, tumor growth and metastasis. Finally, we analyzed the effect of a NRP2 knock-out in 
immune cells during an allergic inflammation in the lung and showed, that T cells and eosinophils were 
reduced. Thus, a knock-out of NRP2 led to an impaired immune response. A possible explanation could 
be because the interaction of immune cells is NRP2 dependent or NRP2 is involved in the activation of 
T cells and/or eosinophils. More work needs to be done to elucidate the role of NRP2 during an immune 
response. Furthermore, we showed that a NRP2 knock-out in T cells led to an impaired expression of 
cytokine genes including IL-13, IL-5 and IL-10. A closer analysis could show if the gene expression has 
an impact on the impaired inflammation and might explain the deregulation of immune cells during the 
allergic response in the lung.  
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5! Summary 
 
Neuropilin-2 (NRP2) is a single transmembrane receptor and was first found in the nervous system to 
play a role in axon guidance. Interestingly, NRP2 was also found on many tumor cells and various 
studies showed that NRP2 is associated with a poor prognosis in different cancers and is involved in 
migration and therapy resistance. We investigated the prognostic potential of NRP2 in the pancreatic 
ductal adenocarcinoma (PDAC) and found out that in contrast to other kinds of cancer a high expression 
of NRP2 is associated with a longer cancer specific survival. We hypothesized that this effect could be 
either triggered through an expression of different interaction partners of NRP2. Both semaphorine 3F 
and VEGFs can bind to NRP2 but have different effects on cancer cells. Semaphorine 3F was found to 
have a great potential as a cancer inhibitor in pancreatic cancer whereas VEGFs are often associated 
with a worse prognosis. Both compete for the binding to NRP2. 
Furthermore, we found high expression of NRP2 in tumor-associated macrophages (TAMs) in PDACs. 
Until now, NRP2 expression and function is poorly analyzed in the immune system. Therefore, we next 
focused on the investigation of NRP2 in the immune system during cancer progression. We used 
LysM:cre-NRP2LoxP/LoxP (conditional knock-out of NRP2 in macrophages) and Vav:cre-NRP2LoxP/LoxP 
(conditional knock-out in all immune cells) for our experiments. We showed that NRP2 is upregulated 
during the differentiation/maturation of macrophages. Next, we injected LLC cells subcutaneously to 
analyze the effect of NRP2 knock-out in macrophages (LysM:cre) or in the all immune cells (Vav:cre). 
No difference was detected in tumor size, but the vascularization was impaired in both mouse models. 
Different tumor models with extended tumor growth times and metastasis should be performed next to 
proof the importance of NRP2 in immune cells during tumor progression. 
Due to the broad expression of NRP2 in the immune system we used the Vav:cre-NRP2LoxP/LoxP mouse 
to investigate the role of NRP2 during an immune response. We used a mild allergic inflammation model 
of the lung and analyzed the different immune cell populations. Interestingly, T cells and eosinophils 
were reduced during the inflammation indicating, that the conditional knock-out of NRP2 is inhibiting 
the immune response. We further analyzed the role of NRP2 in T cells and found out, that the expression 
of NRP2 is very different in the various T cell populations. CD8+ T cells express ca. 10 times as much 
mRNA for NRP2 compared to CD4+ T cells. Also, the CD4 subpopulation showed a diverse expression 
of NRP2. Th2 and Th17 express a lot of NRP2 and Treg and Th1 very low levels. These results suggest 
an important role of NRP2 in certain cells. The knock-out of NRP2 in Th2 cells leads to an upregulation 
of IL-13, IL-5 and IL10.  
We first showed the importance of NRP2 during an immune response and found interesting regulations 
in immune cell populations and important cytokines. More work needs to be done to understand the 
functions of NRP2 during an immune response. 
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